,	O
CH12	O
,	O
and	O
J558	O
)	O
express	O
PPAR-gamma	O
mRNA	O
and	O
,	O
by	O
Western	O
blot	O
analysis	O
,	O
the	O
67-kDa	B-protein
PPAR-gamma	I-protein
protein	I-protein
.	O
15-Deoxy-Delta	O
(	O
12	O
,	O
14	O
)	O
-PGJ	O
(	O
2	O
)	O
(	O
15d-PGJ	O
(	O
2	O
)	O
)	O
,	O
a	O
PPAR-gamma	O
agonist	O
,	O
has	O
a	O
dose-dependent	O
antiproliferative	O
and	O
cytotoxic	O
effect	O
on	O
normal	O
and	O
malignant	O
B	O
cells	O
as	O
shown	O
by	O
[	O
(	O
3	O
)	O
H	O
]	O
thymidine	O
and	O
3-	O
[	O
4	O
,	O
5-dimethylthiazol-2-yl	O
]	O
-2	O
,	O
5-diphenyltetrazolium	O
bromide	O
assays	O
.	O
Only	O
PPAR-gamma	O
agonists	O
(	O
thiazolidinediones	O
)	O
,	O
and	O
not	O
PPAR-alpha	O
agonists	O
,	O
mimicked	O
the	O
effect	O
of	O
15d-PGJ	O
(	O
2	O
)	O
on	O
B-lineage	O
cells	O
,	O
indicating	O
that	O
the	O
mechanism	O
by	O
which	O
15d-PGJ	O
(	O
2	O
)	O
negatively	O
affects	O
B-lineage	O
cells	O
involves	O
in	O
part	O
PPAR-gamma	O
.	O
The	O
mechanism	O
by	O
which	O
PPAR-gamma	O
agonists	O
induce	O
cytotoxicity	O
is	O
via	O
apoptosis	O
,	O
as	O
shown	O
by	O
annexin	O
V	O
staining	O
and	O
as	O
confirmed	O
by	O
DNA	O
fragmentation	O
detected	O
using	O
the	O
TUNEL	O
assay	O
.	O
Interestingly	O
,	O
addition	O
of	O
PGF	O
(	O
2alpha	O
)	O
,	O
which	O
was	O
not	O
known	O
to	O
affect	O
lymphocytes	O
,	O
dramatically	O
attenuated	O
the	O
deleterious	O
effects	O
of	O
PPAR-gamma	O
agonists	O
on	O
B	O
lymphomas	O
.	O
Surprisingly	O
,	O
15d-PGJ	O
(	O
2	O
)	O
induced	O
a	O
massive	O
increase	O
in	O
nuclear	B-protein
mitogen-activated	I-protein
protein	I-protein
kinase	I-protein
activation	O
,	O
and	O
pretreatment	O
with	O
PGF	O
(	O
2alpha	O
)	O
blunted	O
the	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
activation	O
.	O
This	O
is	O
the	O
first	O
study	O
evaluating	O
PPAR-gamma	O
expression	O
and	O
its	O
significance	O
on	O
B	O
lymphocytes	O
.	O
PPAR-gamma	O
agonists	O
may	O
serve	O
as	O
a	O
counterbalance	O
to	O
the	O
stimulating	O
effects	O
of	O
other	O
PGs	O
,	O
namely	O
PGE	O
(	O
2	O
)	O
,	O
which	O
promotes	O
B	O
cell	O
differentiation	O
.	O
Finally	O
,	O
the	O
use	O
of	O
PGs	O
,	O
such	O
as	O
15d-PGJ	O
(	O
2	O
)	O
,	O
and	O
synthetic	O
PPAR-gamma	O
agonists	O
to	O
induce	O
apoptosis	O
in	O
B-lineage	O
cells	O
may	O
lead	O
to	O
the	O
development	O
of	O
novel	O
therapies	O
for	O
fatal	O
B	O
lymphomas	O
Inhibition	O
of	O
STAT3	B-protein
signaling	O
leads	O
to	O
apoptosis	O
of	O
leukemic	O
large	O
granular	O
lymphocytes	O
and	O
decreased	O
Mcl-1	B-protein
expression	O
.	O
Large	O
granular	O
lymphocyte	O
(	O
LGL	O
)	O
leukemia	O
is	O
characterized	O
by	O
the	O
expansion	O
of	O
antigen-activated	O
cytotoxic	O
T	O
lymphocytes	O
.	O
These	O
leukemic	O
cells	O
are	O
resistant	O
to	O
Fas-mediated	O
apoptosis	O
despite	O
expressing	O
high	O
levels	O
of	O
Fas	B-protein
.	O
We	O
found	O
that	O
leukemic	O
LGL	O
from	O
19	O
patients	O
displayed	O
high	O
levels	O
of	O
activated	B-protein
STAT3	I-protein
.	O
Treatment	O
of	O
leukemic	O
LGL	O
with	O
the	O
JAK-selective	B-protein
tyrosine	I-protein
kinase	I-protein
inhibitor	I-protein
AG-490	I-protein
induced	O
apoptosis	O
with	O
a	O
corresponding	O
decrease	O
in	O
STAT	O
-DNA	O
binding	O
activity	O
.	O
Moreover	O
,	O
using	O
an	O
antisense	O
oligonucleotide	O
approach	O
to	O
diminish	O
STAT3	O
expression	O
,	O
we	O
found	O
that	O
Fas	O
sensitivity	O
was	O
restored	O
in	O
leukemic	O
LGL	O
.	O
AG-490-induced	O
apoptosis	O
in	O
leukemic	O
LGL	O
was	O
independent	O
of	O
Bcl-xL	B-protein
or	O
Bcl-2	B-protein
expression	O
.	O
However	O
,	O
we	O
found	O
that	O
the	O
Bcl-2-family	B-protein
protein	I-protein
Mcl-1	B-protein
was	O
significantly	O
reduced	O
by	O
AG-490	O
treatment	O
.	O
Activated	B-protein
STAT3	I-protein
was	O
shown	O
to	O
bind	O
an	O
SIE-related	O
element	O
in	O
the	O
murine	O
mcl-1	O
promoter	O
.	O
Using	O
a	O
luciferase	O
reporter	O
assay	O
,	O
we	O
demonstrated	O
that	O
v-src	O
overexpression	O
in	O
NIH3T3	O
induced	O
STAT3	B-protein
-dependent	O
transcriptional	O
activity	O
from	O
the	O
mcl-1	O
promoter	O
and	O
increased	O
endogenous	B-protein
Mcl-1	I-protein
protein	I-protein
levels	O
.	O
We	O
conclude	O
that	O
STAT3	O
activation	O
contributed	O
to	O
accumulation	O
of	O
the	O
leukemic	O
LGL	O
clones	O
.	O
These	O
findings	O
suggest	O
that	O
investigation	O
should	O
focus	O
on	O
novel	O
strategies	O
targeting	O
STAT3	B-protein
in	O
the	O
treatment	O
of	O
LGL	O
leukemia	O
.	O
Decreased	O
immediate	O
inflammatory	O
gene	O
induction	O
in	O
activating	O
transcription	O
factor-2	O
mutant	O
mice	O
.	O
Transcription	B-protein
factor	I-protein
activating	I-protein
transcription	I-protein
factor	I-protein
(	O
ATF	B-protein
)	O
-2	O
is	O
activated	O
by	O
inflammatory	O
signals	O
transduced	O
by	O
the	O
JNK	B-protein
and	O
p38	B-protein
MAP	I-protein
kinase	I-protein
pathways	O
.	O
To	O
better	O
define	O
the	O
role	O
of	O
ATF-2	B-protein
in	O
inflammation	O
,	O
adult	O
mice	O
expressing	O
small	O
amounts	O
of	O
a	O
mutant	B-protein
ATF-2	I-protein
protein	I-protein
were	O
challenged	O
with	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
anti-CD3	B-protein
antibody	I-protein
or	O
virus	O
.	O
Within	O
3	O
h	O
of	O
challenge	O
by	O
LPS	O
,	O
ATF-2	B-protein
mutant	O
mice	O
had	O
decreased	O
induction	O
of	O
the	O
adhesion	B-protein
molecules	I-protein
E-selectin	B-protein
,	O
P-selectin	O
and	O
VCAM-1	B-protein
as	O
well	O
as	O
the	O
cytokines	B-protein
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
,	O
IL-1beta	O
and	O
IL-6	O
compared	O
with	O
control	O
mice	O
.	O
Stimulation	O
of	O
T	O
lymphocytes	O
by	O
anti-CD3	B-protein
antibody	I-protein
also	O
showed	O
less	O
induction	O
of	O
IL-1	B-protein
and	O
IL-6	B-protein
in	O
ATF-2	B-protein
mutant	O
tissues	O
.	O
ATF-2	B-protein
mutant	O
thymocytes	O
treated	O
with	O
anti-CD3	B-protein
antibody	I-protein
in	O
vitro	O
demonstrated	O
reduced	O
induction	O
of	O
c-Jun	B-protein
,	O
JunB	B-protein
,	O
JunD	B-protein
and	O
Fra-2	B-protein
.	O
However	O
,	O
similar	O
to	O
what	O
was	O
observed	O
after	O
p38	B-protein
kinase	I-protein
inhibition	O
in	O
normal	O
mice	O
,	O
relative	O
ATF-2	O
deficiency	O
did	O
not	O
prevent	O
the	O
development	O
of	O
a	O
mononuclear	O
cell	O
infiltrate	O
in	O
the	O
week	O
following	O
an	O
inflammatory	O
stimulus	O
.	O
ATF-2	O
mutant	O
mice	O
proved	O
more	O
susceptible	O
to	O
death	O
than	O
control	O
mice	O
from	O
LPS	O
plus	O
D-galactosamine	O
injection	O
or	O
Coxsackievirus	O
B3	O
infection	O
and	O
had	O
a	O
higher	O
incidence	O
of	O
mononuclear	O
pulmonary	O
infiltrates	O
after	O
exposure	O
to	O
Herpes	B-protein
simplex	I-protein
virus-1	I-protein
.	O
ATF-2	B-protein
is	O
essential	O
for	O
maximal	O
immediate	O
induction	O
of	O
adhesion	B-protein
molecules	I-protein
and	O
cytokine	O
genes	O
,	O
but	O
at	O
later	O
time	O
points	O
may	O
even	O
protect	O
against	O
overactive	O
immune	O
responses	O
.	O
LIGHT	O
,	O
a	O
TNF-like	O
molecule	O
,	O
costimulates	O
T	O
cell	O
proliferation	O
and	O
is	O
required	O
for	O
dendritic	O
cell	O
-mediated	O
allogeneic	O
T	O
cell	O
response	O
.	O
LIGHT	O
is	O
a	O
recently	O
identified	O
member	O
of	O
the	O
TNF	B-protein
superfamily	I-protein
and	I-protein
its	I-protein
receptors	I-protein
,	O
herpesvirus	O
entry	O
mediator	O
and	O
lymphotoxin	B-protein
beta	I-protein
receptor	I-protein
,	O
are	O
found	O
in	O
T	O
cells	O
and	O
stromal	O
cells	O
.	O
In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
LIGHT	B-protein
is	O
selectively	O
expressed	O
on	O
immature	O
dendritic	O
cells	O
(	O
DCs	O
)	O
generated	O
from	O
human	O
PBMCs	O
.	O
In	O
contrast	O
,	O
LIGHT	B-protein
is	O
not	O
detectable	O
in	O
DCs	O
either	O
freshly	O
isolated	O
from	O
PBMCs	O
or	O
rendered	O
mature	O
in	O
vitro	O
by	O
LPS	O
treatment	O
.	O
Blockade	O
of	O
LIGHT	O
by	O
its	O
soluble	B-protein
receptors	I-protein
,	O
lymphotoxin	O
beta	O
receptor-Ig	O
or	O
HVEM-Ig	O
,	O
inhibits	O
the	O
induction	O
of	O
DC	B-protein
-mediated	O
primary	O
allogeneic	O
T	O
cell	O
response	O
.	O
Furthermore	O
,	O
engagement	O
of	O
LIGHT	O
costimulates	O
human	O
T	O
cell	O
proliferation	O
,	O
amplifies	O
the	O
NF-kappaB	O
signaling	O
pathway	O
,	O
and	O
preferentially	O
induces	O
the	O
production	O
of	O
IFN-gamma	B-protein
,	O
but	O
not	O
IL-4	B-protein
,	O
in	O
the	O
presence	O
of	O
an	O
antigenic	O
signal	O
.	O
Our	O
results	O
suggest	O
that	O
LIGHT	B-protein
is	O
a	O
costimulatory	O
molecule	O
involved	O
in	O
DC	B-protein
-mediated	O
cellular	O
immune	O
responses	O
.	O
Suppression	O
of	O
HIV	O
type	O
1	O
replication	O
by	O
a	O
dominant-negative	B-protein
Ets-1	I-protein
mutant	I-protein
.	O
Activity	O
of	O
the	O
distal	O
region	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV-1	O
)	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
,	O
which	O
contains	O
binding	O
sites	O
for	O
the	O
Ets-1	B-protein
and	I-protein
USF-1	I-protein
proteins	I-protein
,	O
is	O
integral	O
for	O
HIV-1	O
replication	O
.	O
The	O
Ets-1	B-protein
and	I-protein
USF-1	I-protein
proteins	I-protein
play	O
a	O
critical	O
role	O
in	O
the	O
activity	O
of	O
the	O
HIV-1	O
LTR	O
distal	O
enhancer	O
region	O
,	O
as	O
indicated	O
by	O
the	O
potent	O
dominant	O
negative	O
effect	O
of	O
a	O
mutant	B-protein
Ets-1	I-protein
lacking	I-protein
trans-activation	I-protein
domains	I-protein
on	O
the	O
transcriptional	O
activity	O
of	O
the	O
LTR	O
.	O
To	O
determine	O
the	O
biological	O
relevance	O
of	O
the	O
Ets-1	B-protein
and	I-protein
USF-1	I-protein
proteins	I-protein
in	O
HIV-1	O
replication	O
,	O
we	O
examined	O
the	O
effect	O
of	O
expression	O
of	O
the	O
dominant-negative	O
mutant	O
of	O
Ets-1	B-protein
(	O
dnEts-1	O
)	O
on	O
HIV-1	O
infection	O
of	O
T	O
cells	O
.	O
We	O
demonstrated	O
that	O
expression	O
of	O
dnEts	O
markedly	O
suppressed	O
HIV-1	O
infection	O
of	O
a	O
T	O
cell	O
line	O
.	O
This	O
finding	O
indicates	O
that	O
formation	O
of	O
a	O
transcriptionaly	B-protein
active	I-protein
USF-1/Ets-1	I-protein
complex	I-protein
is	O
important	O
in	O
the	O
productive	O
infection	O
of	O
cells	O
by	O
HIV-1	O
,	O
and	O
suggests	O
that	O
inhibition	O
of	O
the	O
interaction	O
between	O
USF-1	O
and	O
Ets-1	O
with	O
the	O
HIV-1	O
LTR	O
may	O
provide	O
a	O
new	O
target	O
for	O
anti-HIV-1	O
gene	O
therapy	O
.	O
Human	O
eosinophils	O
constitutively	O
express	O
nuclear	B-protein
factor	I-protein
of	O
activated	O
T	O
cells	O
p	O
and	O
c	O
.	O
BACKGROUND	O
:	O
Eosinophils	O
are	O
now	O
known	O
to	O
produce	O
a	O
variety	O
of	O
proinflammatory	B-protein
cytokines	I-protein
,	O
although	O
the	O
molecular	B-protein
factors	I-protein
that	O
regulate	O
their	O
production	O
are	O
poorly	O
understood	O
.	O
The	O
expression	O
of	O
almost	O
all	O
of	O
the	O
cytokines	B-protein
produced	O
by	O
eosinophils	O
,	O
including	O
the	O
proallergic	O
cytokine	O
IL-4	O
,	O
is	O
now	O
known	O
to	O
be	O
regulated	O
at	O
the	O
level	O
of	O
transcription	O
by	O
members	O
of	O
the	O
nuclear	B-protein
factor	I-protein
of	O
activated	O
T	O
cells	O
(	O
NFAT	B-protein
)	I-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
.	O
OBJECTIVE	O
:	O
We	O
sought	O
to	O
characterize	O
the	O
expression	O
of	O
different	O
NFAT	B-protein
proteins	I-protein
in	O
resting	O
and	O
activated	O
eosinophils	O
.	O
METHODS	O
:	O
Nuclear	O
and	O
whole	O
cell	O
extracts	O
were	O
obtained	O
from	O
both	O
peripheral	O
blood	O
eosinophils	O
and	O
those	O
obtained	O
from	O
bronchoalveolar	O
lavage	O
fluid	O
of	O
asthmatic	O
subjects	O
after	O
endobronchial	O
allergen	O
challenge	O
.	O
NFAT	O
expression	O
was	O
determined	O
by	O
using	O
immunoprecipitation	O
and	O
Western	O
blot	O
analysis	O
,	O
DNA-binding	O
assays	O
,	O
and	O
RT-PCR	O
analysis	O
of	O
eosinophil	O
mRNA	O
.	O
RESULTS	O
:	O
Both	O
peripheral	O
blood	O
and	O
bronchoalveolar	O
lavage	O
fluid	O
eosinophils	O
expressed	O
NFATp	B-protein
and	O
NFATc	B-protein
protein	I-protein
.	O
Unlike	O
activated	O
T	O
cells	O
,	O
which	O
express	O
multiple	O
NFATc	O
isoforms	O
,	O
eosinophils	O
preferentially	O
express	O
the	O
approximately	O
85-kd	O
isoform	O
.	O
In	O
addition	O
,	O
eosinophils	O
were	O
found	O
to	O
constitutively	O
express	O
NFATc	O
mRNA	O
.	O
A	O
brief	O
incubation	O
with	O
the	O
T	O
(	O
H	B-protein
)	I-protein
2	I-protein
cytokines	I-protein
IL-4	B-protein
and	O
IL-5	B-protein
was	O
sufficient	O
to	O
induce	O
the	O
nuclear	O
translocation	O
of	O
NFATc	B-protein
.	O
Eosinophil	O
nuclear	O
extracts	O
contain	O
multiple	O
factors	O
that	O
can	O
specifically	O
recognize	O
the	O
IL-4	O
promoter	O
P1	O
NFAT	O
site	O
in	O
DNA-binding	O
assays	O
,	O
including	O
NFATp	B-protein
.	O
CONCLUSION	O
:	O
NFATp	O
and	O
NFATc	O
can	O
regulate	O
the	O
expression	O
of	O
cytokines	B-protein
and	O
other	O
genes	O
in	O
eosinophils	O
but	O
appear	O
to	O
be	O
regulated	O
by	O
a	O
novel	O
signal	O
transduction	O
mechanism	O
in	O
these	O
cells	O
.	O
BLyS	O
BINDS	O
TO	O
B	O
CELLS	O
WITH	O
HIGH	B-protein
AFFINITY	I-protein
AND	I-protein
INDUCES	I-protein
ACTIVATION	I-protein
OF	I-protein
THE	I-protein
TRANSCRIPTION	I-protein
FACTORS	I-protein
NF-kappaB	I-protein
AND	I-protein
ELF-1	I-protein
.	O
B	O
lymphocyte	O
stimulator	O
(	O
BLyS	O
)	O
is	O
a	O
novel	O
member	O
of	O
the	O
TNF	B-protein
family	I-protein
of	I-protein
proteins	I-protein
expressed	O
by	O
myeloid	O
cells	O
as	O
membrane-bound	O
and	O
soluble	O
forms	O
.	O
BLyS	O
was	O
shown	O
to	O
act	O
specifically	O
on	O
B	O
cells	O
,	O
inducing	O
proliferation	O
and	O
immunoglobulin	O
production	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
The	O
present	O
study	O
was	O
undertaken	O
to	O
characterize	O
binding	O
of	O
radiolabeled	O
BLyS	O
to	O
its	O
cognate	B-protein
receptor	I-protein
on	O
human	O
B	O
lymphocytes	O
and	O
examine	O
intracellular	O
events	O
initiated	O
by	O
BLyS	O
binding	O
.	O
Similar	O
to	O
other	O
TNF	B-protein
family	I-protein
members	I-protein
,	O
BLyS	O
is	O
present	O
in	O
solution	O
as	O
a	O
homotrimer	O
as	O
determined	O
by	O
gel	O
filtration	O
chromatography	O
and	O
light	O
scattering	O
analysis	O
.	O
BLyS	O
binding	O
to	O
B	O
cells	O
is	O
specific	O
as	O
other	O
TNF	B-protein
family	I-protein
members	I-protein
tested	O
did	O
not	O
compete	O
for	O
(	O
125	O
)	O
I-	O
BLyS	O
binding	O
.	O
Analysis	O
of	O
equilibrium	O
binding	O
of	O
(	O
125	O
)	O
I-labeled	O
BLyS	O
to	O
purified	O
human	O
tonsillar	O
B	O
cells	O
demonstrated	O
saturable	O
binding	O
.	O
Scatchard	O
analysis	O
of	O
the	O
binding	O
data	O
revealed	O
a	O
single	O
class	O
of	O
high-affinity	O
binding	O
on	O
human	O
B	O
cells	O
with	O
approximately	O
2600	O
binding	O
sites	O
per	O
cell	O
and	O
an	O
apparent	O
dissociation	O
constant	O
(	O
K	O
(	O
D	O
)	O
)	O
of	O
about	O
0.1	O
nM	O
.	O
In	O
addition	O
we	O
report	O
that	O
BLyS	O
binding	O
to	O
B	O
cells	O
results	O
in	O
the	O
activation	O
of	O
NF-kappaB	B-protein
and	O
the	O
Ets	B-protein
family	I-protein
transcription	I-protein
factor	I-protein
,	O
ELF-1	O
,	O
and	O
in	O
the	O
induction	O
of	O
mRNA	O
for	O
Polo-like	B-protein
kinase	I-protein
(	O
PLK	O
)	O
.	O
Copyright	O
2001	O
Academic	O
Press	O
.	O
Design	O
and	O
use	O
of	O
an	O
inducibly	O
activated	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
Nef	O
to	O
study	O
immune	O
modulation	O
.	O
The	O
Nef	B-protein
protein	I-protein
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
has	O
been	O
shown	O
to	O
enhance	O
the	O
infectivity	O
of	O
virus	O
particles	O
,	O
downmodulate	B-protein
cell	I-protein
surface	I-protein
proteins	I-protein
,	O
and	O
associate	O
with	O
many	B-protein
intracellular	I-protein
proteins	I-protein
that	O
are	O
thought	O
to	O
facilitate	O
HIV	O
infection	O
.	O
One	O
of	O
the	O
challenges	O
in	O
defining	O
the	O
molecular	O
events	O
regulated	O
by	O
Nef	O
has	O
been	O
obtaining	O
good	O
expression	O
of	O
Nef	B-protein
protein	I-protein
in	O
T	O
cells	O
.	O
This	O
has	O
been	O
attributed	O
to	O
effects	O
of	O
Nef	O
on	O
cell	O
proliferation	O
and	O
apoptosis	O
.	O
We	O
have	O
designed	O
a	O
Nef	B-protein
protein	I-protein
that	O
is	O
readily	O
expressed	O
in	O
T-cell	O
lines	O
and	O
whose	O
function	O
is	O
inducibly	O
activated	O
.	O
It	O
is	O
composed	O
of	O
a	O
fusion	O
between	O
full-length	O
Nef	O
and	O
the	O
estrogen	B-protein
receptor	I-protein
hormone-binding	I-protein
domain	I-protein
(	O
Nef-ER	O
)	O
.	O
The	O
Nef-ER	O
is	O
kept	O
in	O
an	O
inactive	O
state	O
due	O
to	O
steric	O
hindrance	O
,	O
and	O
addition	O
of	O
the	O
membrane-permeable	O
drug	O
4-hydroxytamoxifen	O
(	O
4-HT	O
)	O
,	O
which	O
binds	O
to	O
the	O
ER	B-protein
domain	I-protein
,	O
leads	O
to	O
inducible	O
activation	O
of	O
Nef-ER	O
within	O
cells	O
.	O
We	O
demonstrate	O
that	O
Nef-ER	O
inducibly	O
associates	O
with	O
the	O
62-kDa	O
Ser/Thr	O
kinase	O
and	O
is	O
localized	O
to	O
specific	O
membrane	O
microdomains	O
(	O
lipid	O
rafts	O
)	O
only	O
after	O
activation	O
.	O
Using	O
this	O
inducible	O
Nef	O
,	O
we	O
also	O
compared	O
the	O
specific	O
requirements	O
for	O
CD4	O
and	O
HLA-A2	O
downmodulation	O
in	O
a	O
SupT1	O
T-cell	O
line	O
.	O
Half-maximal	O
downmodulation	O
of	O
cell	O
surface	O
CD4	O
required	O
very	O
little	O
active	O
Nef-ER	O
and	O
occurred	O
as	O
early	O
as	O
4	O
h	O
after	O
addition	O
of	O
4-HT	O
.	O
In	O
contrast	O
,	O
50	O
%	O
downmodulation	O
of	O
HLA-A2	O
by	O
Nef	O
required	O
16	O
to	O
24	O
h	O
and	O
about	O
50-	O
to	O
100-fold-greater	O
concentrations	O
of	O
4-HT	O
.	O
These	O
data	O
suggest	O
that	O
HLA-A2	O
downmodulation	O
may	O
require	O
certain	O
threshold	O
levels	O
of	O
active	O
Nef	O
.	O
The	O
differential	O
timing	O
of	O
CD4	O
and	O
HLA-A2	O
downmodulation	O
may	O
have	O
implications	O
for	O
HIV	O
pathogenesis	O
and	O
immune	O
evasion	O
.	O
Regulation	O
of	O
chemokine	O
mRNA	O
expression	O
in	O
a	O
rat	O
model	O
of	O
vanadium-induced	O
pulmonary	O
inflammation	O
.	O
Environmental	O
and	O
occupational	O
exposure	O
to	O
vanadium	O
dusts	O
results	O
in	O
toxic	O
effects	O
mainly	O
confined	O
to	O
the	O
respiratory	O
system	O
.	O
Using	O
a	O
rat	O
model	O
of	O
acute	O
lung	O
inflammation	O
induced	O
by	O
intratracheal	O
instillation	O
of	O
sodium	O
metavanadate	O
(	O
NaVO3	O
)	O
at	O
the	O
dose	O
of	O
200	O
microg	O
V/kg	O
,	O
we	O
investigated	O
the	O
relationship	O
between	O
the	O
cytologic	O
characterization	O
of	O
pulmonary	O
inflammation	O
and	O
the	O
expression	O
of	O
chemokine	O
mRNA	O
.	O
Significant	O
polymorphonuclear	O
leukocyte	O
(	O
PMN	O
)	O
influx	O
(	O
P	O
<	O
0.01	O
)	O
into	O
the	O
lung	O
was	O
noted	O
4	O
h	O
after	O
NaVO3	O
instillation	O
,	O
whereas	O
alveolar	O
macrophages	O
(	O
AMs	O
)	O
in	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
cells	O
appeared	O
to	O
decrease	O
significantly	O
.	O
In	O
contrast	O
,	O
neither	O
PMNs	O
nor	O
AMs	O
changed	O
substantially	O
1	O
h	O
after	O
NaVO3	O
instillation	O
.	O
By	O
Northern	O
analysis	O
,	O
macrophage	B-protein
inflammatory	I-protein
protein	I-protein
(	O
MIP	O
)	O
-2	O
mRNA	O
in	O
BAL	O
cells	O
increased	O
markedly	O
1	O
h	O
after	O
NaVO3	O
instillation	O
and	O
reduced	O
a	O
little	O
bit	O
at	O
4	O
h	O
,	O
whereas	O
MIP-1alpha	O
mRNA	O
in	O
BAL	O
cells	O
was	O
expressed	O
relatively	O
high	O
1	O
h	O
after	O
NaVO3	O
instillation	O
,	O
although	O
a	O
basal	O
expression	O
was	O
detected	O
in	O
control	O
group	O
,	O
and	O
returned	O
rapidly	O
nearly	O
to	O
control	O
level	O
at	O
4	O
h	O
.	O
Since	O
MIP-2	B-protein
is	O
a	O
potent	O
PMN	O
chemoattractant	O
and	O
MIP-1alpha	B-protein
is	O
a	O
potent	O
macrophage/monocyte	O
chemoattractant	O
has	O
been	O
well	O
known	O
.	O
The	O
facts	O
that	O
PMN	O
influx	O
was	O
preceded	O
by	O
increased	O
MIP-2	O
mRNA	O
expression	O
,	O
suggesting	O
that	O
MIP-2	B-protein
is	O
involved	O
in	O
the	O
development	O
of	O
NaVO3-induced	O
pulmonary	O
inflammation	O
,	O
whereas	O
increased	O
MIP-1alpha	O
mRNA	O
expression	O
was	O
followed	O
by	O
decreased	O
AMs	O
in	O
BAL	O
cells	O
,	O
suggesting	O
AMs	O
might	O
be	O
activated	O
by	O
MIP-1alpha	B-protein
,	O
adherent	O
to	O
the	O
lining	O
surface	O
of	O
the	O
airways	O
and	O
then	O
resistant	O
to	O
be	O
washed	O
out	O
.	O
To	O
delineate	O
the	O
mechanisms	O
of	O
transcriptional	O
activation	O
,	O
we	O
recently	O
cloned	O
the	O
5'-flanking	O
region	O
of	O
the	O
MIP-2	O
gene	O
.	O
The	O
promotor	O
region	O
contains	O
consensus	O
binding	O
sites	O
for	O
transcription	B-protein
factor	I-protein
nuclear	I-protein
factor	I-protein
kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
and	O
activator	B-protein
protein-1	I-protein
(	O
AP-1	B-protein
)	O
.	O
Using	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
increased	O
nuclear	B-protein
NF-kappaB	I-protein
,	O
not	O
AP-1	B-protein
,	O
binding	O
activity	O
was	O
detected	O
1	O
h	O
after	O
NaVO3	O
instillation	O
,	O
which	O
correlated	O
with	O
the	O
induction	O
of	O
MIP-2	O
mRNA	O
.	O
p65	B-protein
(	I-protein
Rel	I-protein
A	I-protein
)	I-protein
and	I-protein
p50	I-protein
protein	I-protein
appears	O
to	O
be	O
involved	O
in	O
MIP-2	O
NF-kappaB	O
binding	O
.	O
Taken	O
together	O
,	O
our	O
studies	O
suggest	O
that	O
MIP-2	B-protein
is	O
an	O
important	O
mediator	O
of	O
NaVO3-induced	O
pulmonary	O
inflammation	O
in	O
the	O
rat	O
model	O
.	O
In	O
addition	O
,	O
elevated	O
MIP-2	O
mRNA	O
levels	O
are	O
accompanied	O
by	O
increased	O
NF-kappaB	O
binding	O
activity	O
in	O
BAL	O
cells	O
,	O
suggesting	O
possible	O
MIP-2	O
transcriptional	O
regulation	O
through	O
NF-kappaB	B-protein
.	O
Activation	O
of	O
signal	O
transduction	O
and	O
apoptosis	O
in	O
healthy	O
lymphomonocytes	O
exposed	O
to	O
bystander	O
HIV-1-infected	O
cells	O
.	O
Persistent	O
activation	O
of	O
the	O
immune	O
system	O
is	O
one	O
of	O
the	O
hallmarks	O
of	O
HIV-1	O
infection	O
.	O
In	O
this	O
study	O
we	O
analysed	O
the	O
induction	O
of	O
factors	O
involved	O
in	O
cytokine	O
signal	O
transduction	O
,	O
such	O
as	O
STAT	B-protein
1	I-protein
proteins	I-protein
and	O
IRF-1	O
mRNA	O
,	O
in	O
normal	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
exposed	O
to	O
HIV-infected	O
cells	O
,	O
and	O
the	O
induction	O
of	O
apoptosis	O
.	O
Western	O
blot	O
analyses	O
and	O
reverse	O
transcriptase-polymerase	O
chain	O
reaction	O
results	O
indicate	O
that	O
both	O
cells	O
infected	O
with	O
a	O
X4	O
strain	O
and	O
cells	O
infected	O
with	O
a	O
R5	O
strain	O
are	O
able	O
to	O
increase	O
intracellular	O
levels	O
of	O
STAT	B-protein
1alpha	I-protein
and	I-protein
beta	I-protein
proteins	I-protein
as	O
well	O
as	O
IRF-1	O
mRNA	O
.	O
This	O
effect	O
was	O
prevented	O
by	O
neutralizing	B-protein
antibodies	I-protein
against	O
interferon-alpha	B-protein
(	O
IFN-alpha	B-protein
)	O
.	O
HIV-1-infected	O
cells	O
dose-dependently	O
induced	O
apoptotic	O
commitment	O
in	O
normal	O
PBMC	O
,	O
as	O
revealed	O
by	O
DNA	O
fragmentation	O
analysis	O
,	O
but	O
this	O
was	O
not	O
accompanied	O
by	O
an	O
increase	O
of	O
caspase-3	B-protein
activity	O
,	O
even	O
if	O
a	O
slight	O
up-regulation	O
of	O
IL-1beta-converting	O
enzyme	O
mRNA	O
was	O
detected	O
.	O
Apoptosis	O
induction	O
could	O
be	O
abrogated	O
mainly	O
by	O
antibodies	B-protein
against	O
tumour	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
by	O
antibodies	B-protein
against	O
IFN-gamma	B-protein
.	O
All	O
these	O
findings	O
suggest	O
that	O
uninfected	O
PBMC	O
can	O
undergo	O
activation	O
of	O
signal	O
transduction	O
and	O
apoptosis	O
after	O
exposure	O
to	O
bystander	O
HIV-infected	O
cells	O
,	O
subsequent	O
to	O
the	O
induction	O
of	O
cytokines	B-protein
such	O
as	O
IFNs	O
and	O
TNF-alpha	B-protein
.	O
The	O
physical	O
association	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
theta	O
with	O
a	O
lipid	O
raft-associated	O
inhibitor	O
of	O
kappa	B-protein
B	I-protein
factor	I-protein
kinase	I-protein
(	I-protein
IKK	I-protein
)	I-protein
complex	I-protein
plays	O
a	O
role	O
in	O
the	O
activation	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
cascade	O
by	O
TCR	B-protein
and	O
CD28	B-protein
.	O
We	O
investigated	O
the	O
role	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
theta	O
(	O
PKCtheta	O
)	O
in	O
the	O
activation	O
of	O
the	O
NF-kappaB	B-protein
cascade	O
in	O
primary	O
human	O
CD4	O
(	O
+	O
)	O
lymphocytes	O
.	O
Among	O
six	O
or	O
so	O
PKC	O
isoforms	O
expressed	O
in	O
T	O
cells	O
,	O
only	O
PKCtheta	O
participates	O
in	O
the	O
assembly	O
of	O
the	O
supramolecular	O
activation	O
clusters	O
at	O
the	O
contact	O
site	O
of	O
the	O
TCR	O
with	O
Ag	B-protein
.	O
Signaling	O
via	O
both	O
the	O
TCR	B-protein
and	O
CD28	B-protein
is	O
required	O
for	O
optimal	O
activation	O
of	O
the	O
multisubunit	B-protein
IkappaB	I-protein
kinase	I-protein
(	I-protein
IKK	I-protein
)	I-protein
complex	I-protein
in	O
primary	O
human	O
T	O
lymphocytes	O
;	O
this	O
activation	O
could	O
be	O
inhibited	O
by	O
a	O
Ca	O
(	O
2+	O
)	O
-independent	O
PKC	O
isoform	O
inhibitor	O
,	O
rottlerin	O
.	O
Moreover	O
,	O
endogenous	O
PKCtheta	O
physically	O
associates	O
with	O
activated	B-protein
IKK	I-protein
complexes	I-protein
in	O
CD3/CD28-costimulated	O
primary	O
CD4	O
(	O
+	O
)	O
T	O
cells	O
.	O
The	O
same	O
set	O
of	O
stimuli	O
also	O
induced	O
relocation	O
of	O
endogenous	O
PKCtheta	O
and	O
IKKs	O
to	O
a	O
GM1	O
ganglioside-enriched	O
,	O
detergent-insoluble	O
membrane	O
compartment	O
in	O
primary	O
T	O
cells	O
.	O
IKKs	O
recruited	O
to	O
these	O
lipid	O
rafts	O
were	O
capable	O
of	O
phosphorylating	O
a	O
recombinant	O
IkappaBalpha	B-protein
sustrate	O
.	O
Confocal	O
microscopy	O
further	O
demonstrated	O
that	O
exogenously	O
expressed	O
PKCtheta	O
and	O
IKKss	O
colocalize	O
in	O
the	O
membrane	O
of	O
CD3/CD28-costimulated	O
Jurkat	O
T	O
cells	O
.	O
Constitutively	O
active	O
but	O
not	O
kinase-inactive	O
PKCtheta	O
activated	O
IKKbeta	O
in	O
Jurkat	O
T	O
cells	O
.	O
Expression	O
of	O
dominant-active	O
PKCtheta	O
also	O
had	O
stimulatory	O
effects	O
on	O
the	O
CD28	O
response	O
element	O
of	O
the	O
IL-2	O
promoter	O
.	O
Taken	O
together	O
,	O
these	O
data	O
show	O
that	O
the	O
activation	O
of	O
PKCtheta	O
by	O
the	O
TCR	B-protein
and	O
CD28	B-protein
plays	O
an	O
important	O
role	O
in	O
the	O
assembly	O
and	O
activation	O
of	O
IKK	B-protein
complexes	I-protein
in	O
the	O
T	O
cell	O
membrane	O
T-cell	O
-mediated	O
regulation	O
of	O
osteoclastogenesis	O
by	O
signalling	O
cross-talk	O
between	O
RANKL	O
and	O
IFN-gamma	B-protein
.	O
Bone	O
resorption	O
is	O
regulated	O
by	O
the	O
immune	O
system	O
,	O
where	O
T-cell	O
expression	O
of	O
RANKL	B-protein
(	I-protein
receptor	I-protein
activator	I-protein
of	I-protein
nuclear	I-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappaB	I-protein
ligand	I-protein
)	O
,	O
a	O
member	O
of	O
the	O
tumour-necrosis	B-protein
factor	I-protein
family	I-protein
that	O
is	O
essential	O
for	O
osteoclastogenesis	O
,	O
may	O
contribute	O
to	O
pathological	O
conditions	O
,	O
such	O
as	O
autoimmune	O
arthritis	O
.	O
However	O
,	O
whether	O
activated	O
T	O
cells	O
maintain	O
bone	O
homeostasis	O
by	O
counterbalancing	O
the	O
action	O
of	O
RANKL	B-protein
remains	O
unknown	O
.	O
Here	O
we	O
show	O
that	O
T-cell	O
production	O
of	O
interferon	B-protein
(	I-protein
IFN	I-protein
)	I-protein
-gamma	I-protein
strongly	O
suppresses	O
osteoclastogenesis	O
by	O
interfering	O
with	O
the	O
RANKL	O
-RANK	O
signalling	O
pathway	O
.	O
IFN-gamma	O
induces	O
rapid	O
degradation	O
of	O
the	O
RANK	B-protein
adapter	I-protein
protein	I-protein
,	O
TRAF6	O
(	O
tumour	B-protein
necrosis	I-protein
factor	I-protein
receptor-associated	I-protein
factor	I-protein
6	I-protein
)	I-protein
,	O
which	O
results	O
in	O
strong	O
inhibition	O
of	O
the	O
RANKL	B-protein
-induced	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
and	O
JNK	B-protein
.	O
This	O
inhibition	O
of	O
osteoclastogenesis	O
is	O
rescued	O
by	O
overexpressing	O
TRAF6	O
in	O
precursor	O
cells	O
,	O
which	O
indicates	O
that	O
TRAF6	B-protein
is	O
the	O
target	O
critical	O
for	O
the	O
IFN-gamma	O
action	O
.	O
Furthermore	O
,	O
we	O
provide	O
evidence	O
that	O
the	O
accelerated	O
degradation	O
of	O
TRAF6	O
requires	O
both	O
its	O
ubiquitination	O
,	O
which	O
is	O
initiated	O
by	O
RANKL	O
,	O
and	O
IFN-gamma	B-protein
-induced	O
activation	O
of	O
the	O
ubiquitin-proteasome	O
system	O
.	O
Our	O
study	O
shows	O
that	O
there	O
is	O
cross-talk	O
between	O
the	O
tumour	B-protein
necrosis	I-protein
factor	I-protein
and	I-protein
IFN	I-protein
families	I-protein
of	O
cytokines	B-protein
,	O
through	O
which	O
IFN-gamma	B-protein
provides	O
a	O
negative	O
link	O
between	O
T-cell	O
activation	O
and	O
bone	O
resorption	O
.	O
Our	O
results	O
may	O
offer	O
a	O
therapeutic	O
approach	O
to	O
treat	O
the	O
inflammation-induced	O
tissue	O
breakdown	O
.	O
Stromal-derived	B-protein
factor	I-protein
1	I-protein
and	O
thrombopoietin	B-protein
regulate	O
distinct	O
aspects	O
of	O
human	O
megakaryopoiesis	O
.	O
The	O
role	O
of	O
the	O
chemokine	B-protein
binding	I-protein
stromal-derived	I-protein
factor	I-protein
1	I-protein
(	O
SDF-1	B-protein
)	O
in	O
normal	O
human	O
megakaryopoiesis	O
at	O
the	O
cellular	O
and	O
molecular	O
levels	O
and	O
its	O
comparison	O
with	O
that	O
of	O
thrombopoietin	O
(	O
TPO	B-protein
)	O
have	O
not	O
been	O
determined	O
.	O
In	O
this	O
study	O
it	O
was	O
found	O
that	O
SDF-1	B-protein
,	O
unlike	O
TPO	B-protein
,	O
does	O
not	O
stimulate	B-protein
alpha	I-protein
(	I-protein
IIb	I-protein
)	I-protein
beta	I-protein
(	I-protein
3	I-protein
)	O
(	O
+	O
)	O
cell	O
proliferation	O
or	O
differentiation	O
or	O
have	O
an	O
antiapoptotic	O
effect	O
.	O
However	O
,	O
it	O
does	O
induce	O
chemotaxis	O
,	O
trans-Matrigel	O
migration	O
,	O
and	O
secretion	O
of	O
matrix	B-protein
metalloproteinase	I-protein
9	I-protein
(	O
MMP-9	O
)	O
and	O
vascular	B-protein
endothelial	I-protein
growth	I-protein
factor	I-protein
(	O
VEGF	O
)	O
by	O
these	O
cells	O
,	O
and	O
both	O
SDF-1	B-protein
and	O
TPO	B-protein
increase	O
the	O
adhesion	O
of	O
alpha	O
(	O
IIb	B-protein
)	I-protein
beta	I-protein
(	I-protein
3	I-protein
)	O
(	O
+	O
)	O
cells	O
to	O
fibrinogen	B-protein
and	O
vitronectin	O
.	O
Investigating	O
the	O
intracellular	O
signaling	O
pathways	O
induced	O
by	O
SDF-1	B-protein
and	O
TPO	B-protein
revealed	O
some	O
overlapping	O
patterns	O
of	O
protein	O
phosphorylation/activation	O
(	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
[	I-protein
MAPK	I-protein
]	O
p42/44	O
,	O
MAPK	B-protein
p38	O
,	O
and	O
AKT	B-protein
[	I-protein
protein	I-protein
kinase	I-protein
B	I-protein
]	I-protein
)	O
and	O
some	O
that	O
were	O
distinct	O
for	O
TPO	B-protein
(	O
eg	O
,	O
JAK-STAT	O
)	O
and	O
for	O
SDF-1	B-protein
(	O
eg	O
,	O
NF-kappa	B-protein
B	I-protein
)	O
.	O
It	O
was	O
also	O
found	O
that	O
though	O
inhibition	O
of	O
phosphatidyl-inositol	B-protein
3-kinase	I-protein
(	O
PI-3K	O
)	O
by	O
LY294002	O
in	O
alpha	O
(	O
IIb	B-protein
)	I-protein
beta	I-protein
(	I-protein
3	I-protein
)	O
(	O
+	O
)	O
cells	O
induced	O
apoptosis	O
and	O
inhibited	O
chemotaxis	O
adhesion	O
and	O
the	O
secretion	O
of	O
MMP-9	O
and	O
VEGF	O
,	O
the	O
inhibition	O
of	O
MAPK	B-protein
p42/44	O
(	O
by	O
the	O
MEK	B-protein
inhibitor	I-protein
U0126	I-protein
)	O
had	O
no	O
effect	O
on	O
the	O
survival	O
,	O
proliferation	O
,	O
and	O
migration	O
of	O
these	O
cells	O
.	O
Hence	O
,	O
it	O
is	O
suggested	O
that	O
the	O
proliferative	O
effect	O
of	O
TPO	B-protein
is	O
more	O
related	O
to	O
activation	O
of	O
the	O
JAK-STAT	O
pathway	O
(	O
unique	O
to	O
TPO	B-protein
)	O
,	O
and	O
the	O
PI-3K-AKT	O
axis	O
is	O
differentially	O
involved	O
in	O
TPO-	O
and	O
SDF-1-dependent	O
signaling	O
.	O
Accordingly	O
,	O
PI-3K	B-protein
is	O
involved	O
in	O
TPO	B-protein
-mediated	O
inhibition	O
of	O
apoptosis	O
,	O
TPO-	O
and	O
SDF-1-regulated	O
adhesion	O
to	O
fibrinogen	B-protein
and	O
vitronectin	O
,	O
and	O
SDF-1	B-protein
-mediated	O
migration	O
.	O
This	O
study	O
expands	O
the	O
understanding	O
of	O
the	O
role	O
of	O
SDF-1	B-protein
and	O
TPO	B-protein
in	O
normal	O
human	O
megakaryopoiesis	O
and	O
indicates	O
the	O
molecular	O
basis	O
of	O
the	O
observed	O
differences	O
in	O
cellular	O
responses	O
.	O
(	O
2000	O
;	O
96	O
:	O
4142-4151	O
)	O
Adhesion	O
of	O
immature	O
and	O
mature	O
T	O
cells	O
induces	O
in	O
human	O
thymic	O
epithelial	O
cells	O
(	O
TEC	O
)	O
activation	O
of	O
IL-6	B-protein
gene	I-protein
trascription	I-protein
factors	I-protein
(	O
NF-kappaB	B-protein
and	O
NF-IL6	B-protein
)	O
and	O
IL-6	O
gene	O
expression	O
:	O
role	O
of	O
alpha3beta1	O
and	O
alpha6beta4	O
integrins	O
.	O
T	O
cell	O
precursors	O
homed	O
to	O
thymus	O
develop	O
in	O
close	O
contact	O
with	O
stromal	O
cells	O
.	O
Among	O
them	O
,	O
thymic	O
epithelial	O
cells	O
(	O
TEC	O
)	O
are	O
known	O
to	O
exert	O
dominant	O
roles	O
in	O
their	O
survival	O
and	O
functional	O
shaping	O
.	O
Key	O
molecules	O
mediating	O
TEC	B-protein
/	O
thymocytes	O
interactions	O
include	O
cytokines	B-protein
and	O
growth	B-protein
factors	I-protein
secreted	O
by	O
the	O
two	O
cell	O
types	O
and	O
adhesion	B-protein
receptors	I-protein
mediating	O
cell	O
contact	O
.	O
Signaling	O
events	O
triggered	O
in	O
thymocytes	O
by	O
adhesion	O
to	O
epithelial	O
cells	O
have	O
been	O
extensively	O
investigated	O
,	O
whereas	O
little	O
is	O
known	O
on	O
the	O
opposite	O
phenomenon	O
.	O
We	O
have	O
previously	O
investigated	O
this	O
issue	O
in	O
a	O
co-culture	O
system	O
composed	O
of	O
TEC	O
cultures	O
derived	O
from	O
human	O
normal	O
thymus	O
and	O
heterologous	O
thymocytes	O
.	O
We	O
demonstrated	O
that	O
thymocytes	O
adhere	O
to	O
TEC	O
involving	O
beta1	O
and	O
beta4	O
integrins	O
and	O
induce	O
the	O
clustering	O
of	O
alpha3beta1	O
and	O
alpha6beta4	O
heterodimers	O
at	O
the	O
TEC	O
surface	O
.	O
In	O
addition	O
thymocyte	O
adhesion	O
was	O
followed	O
by	O
activation	O
of	O
NF-kappaB	B-protein
and	O
NF-IL6	B-protein
gene	I-protein
transcription	I-protein
factors	I-protein
and	O
enhanced	O
IL-6	B-protein
production	O
.	O
The	O
two	O
latter	O
phenomena	O
were	O
reproduced	O
by	O
the	O
cross-linking	O
of	O
the	O
alpha3	O
,	O
alpha6	O
,	O
beta1	O
and	O
beta4	O
integrins	O
,	O
thus	O
implying	O
that	O
the	O
alpha3beta1	O
and	O
alpha6beta4	O
heterodimers	O
can	O
signal	O
during	O
thymocyte	O
adhesion	O
.	O
We	O
have	O
extended	O
our	O
previous	O
work	O
investigating	O
in	O
the	O
same	O
experimental	O
setting	O
the	O
inducing	O
activity	O
of	O
non	O
stimulated	O
or	O
activated	O
policlonal	O
or	O
clonal	O
mature	O
T	O
cells	O
as	O
representative	O
of	O
the	O
more	O
mature	O
thymocyte	O
subset	O
.	O
We	O
found	O
that	O
adhesion	O
of	O
unstimulated	O
T	O
cell	O
i	O
)	O
involved	O
beta1	O
,	O
but	O
not	O
beta4	O
integrin	O
functions	O
at	O
the	O
surface	B-protein
ii	I-protein
)	O
induced	O
the	O
clustering	O
of	O
alpha3beta1	O
,	O
but	O
not	O
alpha2beta1	O
heterodimers	O
at	O
the	O
TEC	O
surface	O
and	O
iii	O
)	O
up-regulated	O
the	O
nuclear	O
binding	O
activity	O
of	O
NF-kappaB	B-protein
transcription	I-protein
factor	I-protein
and	O
the	O
IL-6	O
secretion	O
.	O
We	O
propose	O
that	O
alpha3beta1	O
and	O
alpha6beta4	O
heterodimers	O
are	O
induced	O
to	O
cluster	O
at	O
the	O
TEC	O
surface	O
recognizing	O
yet	O
unknown	O
cellular	O
ligands	O
differentially	O
expressed	O
during	O
T	O
cell	O
development	O
.	O
Identification	O
and	O
characterization	O
of	O
SKAT-2	O
,	O
a	O
novel	O
Th2-specific	O
zinc	O
finger	O
gene	O
.	O
We	O
have	O
identified	O
a	O
novel	O
Kruppel-type	O
zinc	O
finger	O
(	O
ZF	O
)	O
gene	O
,	O
SKAT-2	O
,	O
which	O
is	O
selectively	O
expressed	O
by	O
murine	O
Th2	O
cells	O
.	O
The	O
protein	O
encoded	O
by	O
this	O
gene	O
has	O
14	O
C2H2-type	O
ZF	O
tandemly	O
arrayed	O
at	O
its	O
C	B-protein
terminus	I-protein
and	I-protein
N-terminal	I-protein
SCAN	I-protein
box	I-protein
and	I-protein
KRAB	I-protein
domains	I-protein
.	O
SKAT-2	O
is	O
tissue	O
restricted	O
in	O
expression	O
at	O
the	O
RNA	O
level	O
,	O
detectable	O
only	O
in	O
brain	O
and	O
at	O
low	O
levels	O
in	O
kidney	O
and	O
spleen	O
and	O
few	O
hematopoietic	O
cell	O
lines	O
.	O
By	O
in	O
situ	O
hybridization	O
,	O
SKAT-2	O
expression	O
was	O
found	O
to	O
peak	O
in	O
antigen-stimulated	O
CD4	O
(	O
+	O
)	O
T	O
cells	O
after	O
2-3	O
days	O
of	O
culture	O
under	O
Th2	O
but	O
not	O
Th1	O
biasing	O
conditions	O
.	O
This	O
pattern	O
of	O
expression	O
closely	O
mirrored	O
that	O
of	O
GATA-3	B-protein
in	O
the	O
same	O
cells	O
.	O
In	O
transient	O
transfection	O
experiments	O
in	O
phorbol	O
12-myristate	O
13-acetate/ionomycin-stimulated	O
EL4	O
cells	O
,	O
SKAT-2	O
was	O
found	O
to	O
up-regulate	O
the	O
activity	O
of	O
the	O
IL-4	B-protein
but	O
not	O
the	O
IL-5	O
promoter	O
,	O
contrasting	O
with	O
the	O
ability	O
of	O
GATA-3	B-protein
to	O
activate	O
both	O
promoters	O
.	O
This	O
result	O
was	O
confirmed	O
using	O
clones	O
of	O
EL4	O
cells	O
stably	O
expressing	O
an	O
inducible	O
form	O
of	O
SKAT-2	O
,	O
thus	O
SKAT-2	O
is	O
a	O
novel	O
Th2-specific	O
gene	O
that	O
may	O
play	O
a	O
role	O
in	O
selective	O
regulation	O
of	O
cytokine	O
genes	O
in	O
T	O
cells	O
.	O
hsp70	O
interacting	O
protein	O
Hip	O
does	O
not	O
affect	O
glucocorticoid	B-protein
receptor	I-protein
folding	O
by	O
the	O
hsp90-based	O
chaperone	O
machinery	O
except	O
to	O
oppose	O
the	O
effect	O
of	O
BAG-1	O
.	O
Reticulocyte	O
lysate	O
contains	O
a	O
chaperone	O
system	O
that	O
assembles	O
glucocorticoid	B-protein
receptor	I-protein
(	O
GR	B-protein
)	O
.hsp90	O
heterocomplexes	O
.	O
Using	O
purified	B-protein
proteins	I-protein
,	O
we	O
have	O
prepared	O
a	O
five-protein	O
heterocomplex	O
assembly	O
system	O
consisting	O
of	O
two	O
proteins	O
essential	O
for	O
heterocomplex	O
assembly-	O
hsp90	O
and	O
hsp70	B-protein
-and	I-protein
three	I-protein
proteins	I-protein
that	O
act	O
as	O
co-chaperones	O
to	O
enhance	O
assembly-	O
Hop	O
,	O
hsp40	O
,	O
p23	O
[	O
Morishima	O
,	O
Y.	O
,	O
Kanelakis	O
,	O
K.	O
C.	O
,	O
Silverstein	O
,	O
A.	O
M.	O
,	O
Dittmar	O
,	O
K.	O
D.	O
,	O
Estrada	O
,	O
L.	O
,	O
and	O
Pratt	O
,	O
W.	O
B.	O
(	O
2000	O
)	O
J.	O
275	O
,	O
6894-6900	O
]	O
.	O
The	O
hsp70	O
co-chaperone	O
Hip	O
has	O
been	O
recovered	O
in	O
receptor.hsp90	O
heterocomplexes	O
at	O
an	O
intermediate	O
stage	O
of	O
assembly	O
in	O
reticulocyte	O
lysate	O
,	O
and	O
Hip	O
is	O
also	O
thought	O
to	O
be	O
an	O
intrinsic	O
component	O
of	O
the	O
assembly	O
machinery	O
.	O
Here	O
we	O
show	O
that	O
immunodepletion	O
of	O
Hip	O
from	O
reticulocyte	O
lysate	O
or	O
addition	O
of	O
high	O
levels	O
of	O
Hip	O
to	O
the	O
purified	O
five-protein	O
system	O
does	O
not	O
affect	O
GR.hsp90	O
heterocomplex	O
assembly	O
or	O
the	O
activation	O
of	O
steroid	O
binding	O
activity	O
that	O
occurs	O
with	O
assembly	O
.	O
Despite	O
the	O
fact	O
that	O
Hip	B-protein
does	O
not	O
affect	O
assembly	O
,	O
it	O
is	O
recovered	O
in	O
GR.hsp90	O
heterocomplexes	O
assembled	O
by	O
both	O
systems	O
.	O
In	O
the	O
five-protein	O
system	O
,	O
Hip	O
prevents	O
inhibition	O
of	O
assembly	O
by	O
the	O
hsp70	O
co-chaperone	O
BAG-1	O
,	O
and	O
cotransfection	O
of	O
Hip	O
with	O
BAG-1	O
opposes	O
BAG-1	O
reduction	O
of	O
steroid	O
binding	O
activity	O
in	O
COS	O
cells	O
.	O
We	O
conclude	O
that	O
Hip	O
is	O
not	O
a	O
component	O
of	O
the	O
assembly	O
machinery	O
but	O
that	O
it	O
could	O
play	O
a	O
regulatory	O
role	O
in	O
opposition	O
to	O
BAG-1	O
.	O
Cutting	O
edge	O
:	O
STAT6-deficient	O
mice	O
have	O
enhanced	O
tumor	O
immunity	O
to	O
primary	O
and	O
metastatic	O
mammary	O
carcinoma	O
.	O
STAT4	B-protein
and	O
STAT6	B-protein
are	O
essential	O
for	O
the	O
development	O
of	O
CD4	O
(	O
+	O
)	O
Th1	O
and	O
Th2	O
development	O
,	O
respectively	O
.	O
Tumor	O
immunologists	O
have	O
hypothesized	O
that	O
Th1	O
cells	O
are	O
critical	O
in	O
tumor	O
immunity	O
because	O
they	O
facilitate	O
differentiation	O
of	O
CD8	O
(	O
+	O
)	O
T	O
cells	O
,	O
which	O
are	O
potent	O
anti-tumor	O
effectors	O
.	O
We	O
have	O
used	O
STAT4	O
(	O
-/-	O
)	O
and	O
STAT6	B-protein
(	O
-/-	O
)	O
mice	O
to	O
test	O
this	O
hypothesis	O
.	O
BALB/c	O
and	O
knockout	O
mice	O
were	O
challenged	O
in	O
the	O
mammary	O
gland	O
with	O
the	O
highly	O
malignant	O
and	O
spontaneously	O
metastatic	O
BALB/c-derived	O
4T1	O
mammary	O
carcinoma	O
.	O
Primary	O
tumor	O
growth	O
and	O
metastatic	O
disease	O
are	O
reduced	O
in	O
STAT6	B-protein
(	O
-/-	O
)	O
mice	O
relative	O
to	O
BALB/c	O
and	O
STAT4	B-protein
(	O
-/-	O
)	O
mice	O
.	O
Ab	O
depletions	O
demonstrate	O
that	O
the	O
effect	O
is	O
mediated	O
by	O
CD8	O
(	O
+	O
)	O
T	O
cells	O
,	O
and	O
immunized	B-protein
STAT6	I-protein
(	O
-/-	O
)	O
mice	O
have	O
higher	O
levels	O
of	O
4T1-specific	O
CTL	O
than	O
BALB/c	O
or	O
STAT4	B-protein
(	O
-/-	O
)	O
mice	O
.	O
Surprisingly	O
,	O
Th1	O
or	O
Th2	O
cells	O
are	O
not	O
involved	O
,	O
because	O
CD4	O
depletion	O
does	O
not	O
diminish	O
the	O
anti-tumor	O
effect	O
.	O
Therefore	O
,	O
deletion	O
of	O
the	O
STAT6	O
gene	O
facilitates	O
development	O
of	O
potent	O
anti-tumor	O
immunity	O
via	O
a	O
CD4	O
(	O
+	O
)	O
-independent	O
pathway	O
.	O
Activation	O
of	O
oncogenic	B-protein
transcription	I-protein
factor	I-protein
AP-1	I-protein
in	O
T	O
cells	O
infected	O
with	O
human	O
T	O
cell	O
leukemia	O
virus	O
type	O
1	O
.	O
Human	O
T	O
cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
Tax	B-protein
protein	I-protein
transforms	O
primary	O
human	O
T	O
cells	O
in	O
vitro	O
.	O
We	O
previously	O
showed	O
that	O
Tax	B-protein
induces	O
the	O
expression	O
of	O
various	O
family	O
members	O
of	O
the	O
transcription	B-protein
factor	I-protein
AP-1	I-protein
such	O
as	O
c-Jun	B-protein
,	O
JunD	B-protein
,	O
c-Fos	B-protein
,	O
and	O
Fra-1	O
at	O
the	O
mRNA	O
level	O
in	O
T	O
cells	O
.	O
In	O
this	O
study	O
,	O
we	O
have	O
examined	O
the	O
ability	O
of	O
Tax	B-protein
to	O
activate	O
transcription	O
through	O
the	O
AP-1-binding	O
site	O
(	O
AP-1	O
site	O
)	O
.	O
A	O
transient	O
transfection	O
study	O
showed	O
that	O
Tax	B-protein
can	O
activate	O
transcription	O
through	O
the	O
AP-1-binding	O
site	O
in	O
a	O
human	O
T	O
cell	O
line	O
,	O
whereas	O
any	O
combination	O
of	O
AP-1	B-protein
proteins	I-protein
did	O
so	O
much	O
less	O
than	O
Tax	B-protein
,	O
indicating	O
that	O
the	O
activation	O
of	O
the	O
AP-1	O
site	O
by	O
Tax	B-protein
may	O
require	O
a	O
mechanism	O
other	O
than	O
the	O
induction	O
of	O
AP-1	O
mRNA	O
.	O
Fresh	O
peripheral	O
blood	O
leukemia	O
cells	O
of	O
all	O
surveyed	O
ATL	O
patients	O
displayed	O
constitutive	O
AP-1	O
DNA-binding	O
activity	O
,	O
whereas	O
no	O
normal	O
individuals	O
did	O
.	O
However	O
,	O
the	O
HTLV-1	O
genes	O
,	O
including	O
tax	B-protein
,	O
are	O
not	O
significantly	O
expressed	O
in	O
fresh	O
leukemia	O
cells	O
from	O
ATL	O
patients	O
.	O
Our	O
present	O
results	O
suggest	O
that	O
activation	O
of	O
AP-1	B-protein
occurs	O
through	O
Tax-dependent	O
and	O
-independent	O
mechanisms	O
in	O
HTLV-1-infected	O
T	O
cells	O
,	O
which	O
may	O
play	O
some	O
roles	O
in	O
dysregulated	O
phenotypes	O
of	O
HTLV-1-infected	O
cells	O
.	O
2	O
,	O
2	O
'	O
,	O
4	O
,	O
6	O
,	O
6'-pentachlorobiphenyl	O
induces	O
apoptosis	O
in	O
human	O
monocytic	O
cells	O
.	O
Polychlorinatedbiphenyls	O
(	O
PCBs	O
)	O
are	O
a	O
group	O
of	O
persistent	O
and	O
widely	O
dispersed	O
environmental	O
pollutants	O
,	O
some	O
of	O
which	O
may	O
be	O
immunotoxic	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
PCBs	O
on	O
immune	O
system	O
by	O
assessing	O
apoptotic	O
cell	O
death	O
in	O
human	O
monocytic	O
U937	O
cells	O
.	O
Among	O
the	O
various	O
congeners	O
tested	O
,	O
2	O
,	O
2	O
'	O
,	O
4	O
,	O
6	O
,	O
6'-pentachlorobiphenyl	O
(	O
PeCB	O
)	O
,	O
a	O
highly	O
ortho-substituted	O
congener	O
,	O
specifically	O
induced	O
DNA	O
fragmentation	O
,	O
a	O
hallmark	O
of	O
apoptosis	O
,	O
while	O
the	O
other	O
examined	O
di-	O
,	O
tri-	O
,	O
tetra-	O
,	O
and	O
pentachlorobiphenyls	O
did	O
not	O
.	O
To	O
further	O
study	O
the	O
2	O
,	O
2	O
'	O
,	O
4	O
,	O
6	O
,	O
6'-PeCB-induced	O
cell	O
death	O
,	O
various	O
features	O
of	O
apoptosis	O
were	O
examined	O
.	O
2	O
,	O
2	O
'	O
,	O
4	O
,	O
6	O
,	O
6'-PeCB	O
caused	O
a	O
decrease	O
in	O
cell	O
viability	O
and	O
induced	O
cellular	O
morphologic	O
features	O
characteristic	O
of	O
apoptosis	O
such	O
as	O
chromatin	O
aggregation	O
and	O
apoptotic	O
bodies	O
.	O
In	O
addition	O
,	O
caspase-3	O
,	O
an	O
executioner	O
of	O
apoptosis	O
,	O
was	O
activated	O
and	O
its	O
substrate	O
,	O
poly	O
(	O
ADP-ribose	O
)	O
polymerase	O
(	O
PARP	O
)	O
,	O
was	O
cleaved	O
during	O
2	O
,	O
2	O
'	O
,	O
4	O
,	O
6	O
,	O
6'-PeCB-induced	O
apoptosis	O
.	O
In	O
contrast	O
,	O
3	O
,	O
3	O
'	O
,	O
4	O
,	O
4	O
'	O
,	O
5-PeCB	O
,	O
a	O
congener	O
of	O
coplanar	O
structure	O
,	O
as	O
well	O
as	O
2	O
,	O
3	O
,	O
7	O
,	O
8-TCDD	O
did	O
not	O
induce	O
apoptosis	O
in	O
these	O
human	O
monocytic	O
cells	O
,	O
although	O
they	O
potently	O
induced	O
CYP	O
1A1	O
in	O
human	O
hepatoma	O
Hep	O
G2	O
cells	O
.	O
Taken	O
together	O
,	O
the	O
data	O
indicate	O
that	O
2	O
,	O
2	O
'	O
,	O
4	O
,	O
6	O
,	O
6'-PeCB	O
induces	O
apoptosis	O
in	O
human	O
monocytic	O
cells	O
through	O
a	O
mechanism	O
that	O
is	O
independent	O
of	O
the	O
arylhydrocarbon	B-protein
receptor	I-protein
.	O
This	O
suggests	O
a	O
possibly	O
separate	O
mechanism	O
by	O
which	O
PCBs	O
cause	O
immunosuppression	O
.	O
Effects	O
of	O
deregulated	O
Raf	O
activation	O
on	O
integrin	O
,	O
cytokine-receptor	O
expression	O
and	O
the	O
induction	O
of	O
apoptosis	O
in	O
hematopoietic	O
cells	O
.	O
The	O
effects	O
of	O
deregulated	O
Raf	O
activation	O
on	O
the	O
growth	O
and	O
differentiation	O
of	O
hematopoietic	O
cells	O
were	O
investigated	O
.	O
The	O
cytokine-dependent	O
murine	O
myeloid	O
FDC-P1	O
and	O
human	O
erythroleukemic	O
TF-1	O
cell	O
lines	O
were	O
transformed	O
to	O
grow	O
in	O
response	O
to	O
deregulated	O
Raf	O
expression	O
in	O
the	O
absence	O
of	O
exogenous	B-protein
cytokines	I-protein
.	O
The	O
conditionally	O
active	B-protein
Raf	I-protein
proteins	I-protein
were	O
regulated	O
by	O
beta-estradiol	O
as	O
cDNAs	O
containing	O
the	O
Raf	O
catalytic	O
,	O
but	O
lacking	O
negative-regulatory	O
domains	O
,	O
were	O
ligated	O
to	O
the	O
hormone	B-protein
binding	I-protein
domain	I-protein
of	O
the	O
estrogen	B-protein
receptor	I-protein
(	O
deltaRaf	O
:	O
ER	O
)	O
.	O
Continuous	O
deltaRaf	O
expression	O
prevented	O
apoptosis	O
in	O
the	O
absence	O
of	O
exogenous	B-protein
cytokines	I-protein
and	O
altered	O
the	O
morphology	O
of	O
the	O
FD/deltaRaf	O
:	O
ER	O
cells	O
as	O
they	O
grew	O
in	O
large	O
aggregated	O
masses	O
(	O
>	O
100	O
cells	O
)	O
whereas	O
the	O
parental	O
cytokine-dependent	O
FDC-P1	O
cells	O
grew	O
in	O
smaller	O
grape-like	O
clusters	O
(	O
<	O
10	O
cells	O
)	O
.	O
FD/deltaRaf-1	O
:	O
ER	O
cells	O
growing	O
in	O
response	O
to	O
Raf	O
activation	O
displayed	O
decreased	O
levels	O
of	O
the	O
Mac-2	O
and	O
Mac-3	B-protein
molecules	I-protein
on	O
their	O
cell	O
surface	O
.	O
In	O
contrast	O
,	O
when	O
these	O
cells	O
were	O
cultured	O
in	O
IL-3	B-protein
,	O
higher	O
levels	O
of	O
these	O
adhesion	B-protein
molecules	I-protein
were	O
detected	O
.	O
Expression	O
of	O
activated	B-protein
Raf	I-protein
oncoproteins	I-protein
also	O
abrogated	O
cytokine	O
dependency	O
and	O
prevented	O
apoptosis	O
of	O
TF-1	O
cells	O
.	O
Moreover	O
,	O
the	O
differentiation	O
status	O
of	O
these	O
Raf-responsive	O
cells	O
was	O
more	O
immature	O
upon	O
Raf	O
activation	O
as	O
culture	O
with	O
the	O
differentiation-inducing	O
agent	O
phorbol	O
12	O
myristate	O
13-acetate	O
(	O
PMA	O
)	O
and	O
beta-estradiol	O
resulted	O
in	O
decreased	O
levels	O
of	O
the	O
CD11b	B-protein
and	I-protein
CD18	I-protein
integrin	I-protein
molecules	I-protein
on	O
the	O
cell	O
surface	O
.	O
In	O
contrast	O
when	O
the	O
Raf-responsive	O
cells	O
were	O
induced	O
to	O
differentiate	O
with	O
PMA	O
and	O
GM-CSF	B-protein
,	O
in	O
the	O
absence	O
of	O
deltaRaf	O
:	O
ER	O
activation	O
,	O
increased	O
levels	O
of	O
the	O
CD11b	B-protein
and	O
CD18	B-protein
molecules	I-protein
were	O
detected	O
.	O
Retinoic	O
acid	O
(	O
RA	O
)	O
inhibited	O
3H-thymidine	O
incorporation	O
in	O
response	O
to	O
GM-CSF	B-protein
.	O
Interestingly	O
,	O
Raf	O
activation	O
counterbalanced	O
the	O
inhibition	O
of	O
DNA	O
synthesis	O
caused	O
by	O
RA	O
but	O
not	O
PMA	O
.	O
Thus	O
deregulated	O
Raf	O
expression	O
can	O
alter	O
cytokine	O
dependency	O
,	O
integrin	O
expression	O
and	O
the	O
stage	O
of	O
differentiation	O
.	O
These	O
Raf-responsive	O
cell	O
lines	O
will	O
be	O
useful	O
in	O
elucidating	O
the	O
roles	O
of	O
the	O
MAP	B-protein
kinase	I-protein
cascade	I-protein
on	O
hematopoietic	O
cell	O
differentiation	O
and	O
malignant	O
transformation	O
Cyclic	O
AMP	O
activates	O
p38	B-protein
mitogen-activated	I-protein
protein	I-protein
kinase	I-protein
in	O
Th2	O
cells	O
:	O
phosphorylation	O
of	O
GATA-3	B-protein
and	O
stimulation	O
of	O
Th2	O
cytokine	O
gene	O
expression	O
.	O
cAMP	O
is	O
an	O
important	O
second	O
messenger	O
with	O
immunomodulatory	O
properties	O
.	O
Elevation	O
of	O
intracellular	O
cAMP	O
in	O
T	O
cells	O
,	O
induced	O
by	O
agents	O
such	O
as	O
IL-1alpha	B-protein
or	O
PGs	O
,	O
inhibits	O
T	O
cell	O
activation	O
.	O
In	O
effector	O
T	O
cells	O
,	O
an	O
increase	O
in	O
the	O
level	O
of	O
intracellular	O
cAMP	O
inhibits	O
cytokine	O
production	O
in	O
Th1	O
cells	O
but	O
stimulates	O
cytokine	O
production	O
in	O
Th2	O
cells	O
.	O
Here	O
we	O
report	O
that	O
cAMP-induced	O
effects	O
in	O
Th2	O
cells	O
occur	O
independently	O
of	O
the	O
protein	O
kinase	O
A	O
pathway	O
,	O
which	O
is	O
the	O
major	O
mediator	O
of	O
cAMP-induced	O
signaling	O
events	O
in	O
most	O
cell	O
types	O
.	O
Instead	O
,	O
cAMP	O
stimulates	O
activation	O
of	O
p38	B-protein
mitogen-activated	I-protein
protein	I-protein
kinase	I-protein
in	O
Th2	O
cells	O
.	O
This	O
appears	O
to	O
be	O
a	O
Th2	O
-selective	O
event	O
because	O
cAMP	O
barely	O
increased	O
p38	O
phosphorylation	O
in	O
Th1	O
cells	O
.	O
We	O
show	O
that	O
in	O
Th2	O
cells	O
,	O
cAMP	O
promotes	O
the	O
production	O
of	O
both	O
IL-5	O
and	O
IL-13	B-protein
,	O
which	O
play	O
distinct	O
but	O
critical	O
roles	O
in	O
asthma	O
pathogenesis	O
.	O
Our	O
data	O
also	O
show	O
that	O
cAMP	O
causes	O
increased	O
phosphorylation	O
of	O
the	O
transcription	B-protein
factor	I-protein
GATA-3	I-protein
,	O
which	O
we	O
have	O
shown	O
is	O
a	O
critical	O
regulator	O
of	O
Th2	O
cytokine	O
gene	O
expression	O
and	O
,	O
in	O
turn	O
,	O
of	O
airway	O
inflammation	O
in	O
mice	O
.	O
Thus	O
,	O
Th2	O
-specific	O
GATA-3	B-protein
expression	O
and	O
p38	B-protein
mitogen-activated	I-protein
protein	I-protein
kinase	I-protein
activation	O
together	O
provide	O
a	O
molecular	O
basis	O
for	O
the	O
differential	O
effects	O
of	O
cAMP	O
in	O
the	O
two	O
T	O
helper	O
cell	O
subsets	O
.	O
Characterization	O
of	O
IL-4	B-protein
and	O
IL-13	B-protein
signals	O
dependent	O
on	O
the	O
human	O
IL-13	O
receptor	O
alpha	O
chain	O
1	O
:	O
redundancy	O
of	O
requirement	O
of	O
tyrosine	O
residue	O
for	O
STAT3	O
activation	O
.	O
IL-4	O
and	O
IL-13	B-protein
are	O
pleiotropic	B-protein
cytokines	I-protein
whose	O
biological	O
activities	O
overlap	O
with	O
each	O
other	O
.	O
IL-13	B-protein
receptor	I-protein
alpha	I-protein
chain	I-protein
1	I-protein
(	O
IL-13R	B-protein
alpha	I-protein
1	I-protein
)	O
is	O
necessary	O
for	O
binding	O
to	O
IL-13	B-protein
,	O
and	O
the	O
heterodimer	O
composed	O
of	O
IL-13R	B-protein
alpha	I-protein
1	I-protein
and	O
IL-4R	B-protein
alpha	I-protein
chain	I-protein
transduces	O
IL-13	O
and	O
IL-4	B-protein
signals	O
;	O
however	O
,	O
the	O
functional	O
mapping	O
of	O
the	O
intracellular	B-protein
domain	I-protein
of	O
IL-13R	B-protein
alpha	I-protein
1	I-protein
is	O
not	O
fully	O
understood	O
.	O
In	O
this	O
study	O
,	O
we	O
constructed	O
wild	O
and	O
mutated	O
types	O
of	O
human	B-protein
IL-13R	I-protein
alpha	I-protein
1	I-protein
,	O
and	O
analyzed	O
IL-4	B-protein
and	O
IL-13	B-protein
signals	O
using	O
an	O
IL-13R	O
alpha	O
1	O
-transfected	O
human	O
B	O
cell	O
line	O
.	O
Expression	O
of	O
IL-13R	B-protein
alpha	I-protein
1	I-protein
evoked	I-protein
STAT3	I-protein
activation	O
by	O
IL-4	B-protein
and	O
IL-13	B-protein
,	O
and	O
in	O
stimulated	O
human	O
B	O
cells	O
,	O
on	O
which	O
IL-13R	B-protein
alpha	I-protein
1	I-protein
was	O
highly	O
expressed	O
,	O
IL-4	B-protein
and	O
IL-13	B-protein
induced	O
STAT3	O
activation	O
.	O
Replacement	O
of	O
the	O
two	O
tyrosine	O
residues	O
completely	O
abolished	O
STAT3	O
activation	O
,	O
although	O
replacing	O
either	O
tyrosine	O
residue	O
alone	O
retained	O
it	O
.	O
Furthermore	O
,	O
we	O
found	O
that	O
the	O
Box1	O
region	O
and	O
the	O
C-terminal	O
tail	O
of	O
IL-13R	B-protein
alpha	I-protein
1	I-protein
were	O
critical	O
for	O
binding	O
to	O
Tyk2	O
,	O
and	O
activation	O
of	O
Jak1	O
,	O
Tyk2	O
,	O
the	O
insulin	O
receptor	O
substrate-1	O
and	O
STAT6	B-protein
respectively	O
.	O
These	O
results	O
suggest	O
that	O
STAT3	O
activation	O
is	O
involved	O
with	O
IL-4	B-protein
and	O
IL-13	B-protein
signals	O
in	O
human	O
B	O
cells	O
along	O
with	O
the	O
activation	O
of	O
STAT6	B-protein
,	O
and	O
that	O
there	O
is	O
a	O
unique	O
sequence	O
in	O
IL-13R	O
alpha	O
1	O
to	O
activate	O
STAT3	B-protein
.	O
Functional	O
uncoupling	O
of	O
the	O
Janus	B-protein
kinase	I-protein
3-Stat5	O
pathway	O
in	O
malignant	O
growth	O
of	O
human	O
T	O
cell	O
leukemia	O
virus	O
type	O
1-transformed	O
human	O
T	O
cells	O
.	O
Human	O
T	O
cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
transforms	O
cytokine	B-protein
-dependent	O
T	O
lymphocytes	O
and	O
causes	O
adult	O
T	O
cell	O
leukemia	O
.	O
Janus	B-protein
tyrosine	I-protein
kinase	I-protein
(	O
Jak	B-protein
)	I-protein
3	I-protein
and	I-protein
transcription	I-protein
factors	I-protein
Stat5a	B-protein
and	O
Stat5b	B-protein
are	O
essential	O
for	O
the	O
proliferation	O
of	O
normal	O
T	O
cells	O
and	O
are	O
constitutively	O
hyperactivated	O
in	O
both	O
HTLV-1-transformed	O
human	O
T	O
cell	O
lines	O
and	O
lymphocytes	O
isolated	O
from	O
HTLV-1-infected	O
patients	O
;	O
therefore	O
,	O
a	O
critical	O
role	O
for	O
the	O
Jak3-Stat5	O
pathway	O
in	O
the	O
progression	O
of	O
this	O
disease	O
has	O
been	O
postulated	O
.	O
We	O
recently	O
reported	O
that	O
tyrphostin	O
AG-490	O
selectively	O
blocked	O
IL-2	O
activation	O
of	O
Jak3/Stat5	O
and	O
growth	O
of	O
murine	O
T	O
cell	O
lines	O
.	O
Here	O
we	O
demonstrate	O
that	O
disruption	O
of	O
Jak3/Stat5a/b	O
signaling	O
with	O
AG-490	O
(	O
50	O
&	O
mgr	O
;	O
M	O
)	O
blocked	O
the	O
proliferation	O
of	O
primary	O
human	O
T	O
lymphocytes	O
,	O
but	O
paradoxically	O
failed	O
to	O
inhibit	O
the	O
proliferation	O
of	O
HTLV-1-transformed	O
human	O
T	O
cell	O
lines	O
,	O
HuT-102	O
and	O
MT-2	O
.	O
Structural	O
homologues	O
of	O
AG-490	B-protein
also	O
inhibited	O
the	O
proliferation	O
of	O
primary	O
human	O
T	O
cells	O
,	O
but	O
not	O
HTLV-1-infected	O
cells	O
.	O
Disruption	O
of	O
constitutive	O
Jak3/Stat5	O
activation	O
by	O
AG-490	O
was	O
demonstrated	O
by	O
inhibition	O
of	O
1	O
)	O
tyrosine	O
phosphorylation	O
of	O
Jak3	B-protein
,	O
Stat5a	B-protein
(	O
Tyr	O
(	O
694	O
)	O
)	O
,	O
and	O
Stat5b	B-protein
(	O
Tyr	O
(	O
699	O
)	O
)	O
;	O
2	O
)	O
serine	O
phosphorylation	O
of	O
Stat5a	B-protein
(	O
Ser	O
(	O
726	O
)	O
)	O
as	O
determined	O
by	O
a	O
novel	O
phosphospecific	O
Ab	O
;	O
and	O
3	O
)	O
Stat5a/b	O
DNA	O
binding	O
to	O
the	O
Stat5-responsive	O
beta-casein	O
promoter	O
.	O
In	O
contrast	O
,	O
AG-490	O
had	O
no	O
effect	O
on	O
DNA	O
binding	O
by	O
p50/p65	O
components	O
of	O
NF-kappaB	B-protein
,	O
a	O
transcription	B-protein
factor	I-protein
activated	O
by	O
the	O
HTLV-1-encoded	O
phosphoprotein	O
,	O
Tax	B-protein
.	O
Collectively	O
,	O
these	O
data	O
suggest	O
that	O
the	O
Jak3-Stat5	O
pathway	O
in	O
HTLV-1-transformed	O
T	O
cells	O
has	O
become	O
functionally	O
redundant	O
for	O
proliferation	O
.	O
Reversal	O
of	O
this	O
functional	O
uncoupling	O
may	O
be	O
required	O
before	O
Jak3/Stat5	O
inhibitors	O
will	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
this	O
malignancy	O
.	O
The	O
Epstein-Barr	O
virus	O
promoter	O
initiating	O
B-cell	O
transformation	O
is	O
activated	O
by	O
RFX	B-protein
proteins	I-protein
and	O
the	O
B-cell-specific	B-protein
activator	I-protein
protein	I-protein
BSAP/Pax5	I-protein
.	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
-induced	O
B-cell	O
growth	O
transformation	O
,	O
a	O
central	O
feature	O
of	O
the	O
virus	O
'	O
strategy	O
for	O
colonizing	O
the	O
human	O
B-cell	O
system	O
,	O
requires	O
full	O
virus	O
latent	O
gene	O
expression	O
and	O
is	O
initiated	O
by	O
transcription	O
from	O
the	O
viral	O
promoter	O
Wp	O
.	O
Interestingly	O
,	O
when	O
EBV	O
accesses	O
other	O
cell	O
types	O
,	O
this	O
growth-transforming	O
program	O
is	O
not	O
activated	O
.	O
The	O
present	O
work	O
focuses	O
on	O
a	O
region	O
of	O
Wp	O
which	O
in	O
reporter	O
assays	O
confers	O
B-cell	O
-specific	O
activity	O
.	O
Bandshift	O
studies	O
indicate	O
that	O
this	O
region	O
contains	O
three	O
factor	O
binding	O
sites	O
,	O
termed	O
sites	O
B	O
,	O
C	O
,	O
and	O
D	O
,	O
in	O
addition	O
to	O
a	O
previously	O
characterized	O
CREB	O
site	O
.	O
Here	O
we	O
show	O
that	O
site	O
C	O
binds	O
members	O
of	O
the	O
ubiquitously	O
expressed	O
RFX	B-protein
family	I-protein
of	I-protein
proteins	I-protein
,	O
notably	O
RFX1	O
,	O
RFX3	O
,	O
and	O
the	O
associated	B-protein
factor	I-protein
MIBP1	I-protein
,	O
whereas	O
sites	O
B	O
and	O
D	O
both	O
bind	O
the	O
B-cell-specific	B-protein
activator	I-protein
protein	I-protein
BSAP/Pax5	I-protein
.	O
In	O
reporter	O
assays	O
with	O
mutant	O
Wp	O
constructs	O
,	O
the	O
loss	O
of	O
factor	O
binding	O
to	O
any	O
one	O
of	O
these	O
sites	O
severely	O
impaired	O
promoter	O
activity	O
in	O
B	O
cells	O
,	O
while	O
the	O
wild-type	O
promoter	O
could	O
be	O
activated	O
in	O
non-B	O
cells	O
by	O
ectopic	O
BSAP	B-protein
expression	O
.	O
We	O
suggest	O
that	O
Wp	O
regulation	O
by	O
BSAP	B-protein
helps	O
to	O
ensure	O
the	O
B-cell	O
specificity	O
of	O
EBV	O
's	O
growth-transforming	O
function	O
.	O
Activation	O
of	O
the	O
Lck	B-protein
tyrosine	I-protein
protein	I-protein
kinase	I-protein
by	O
the	O
Herpesvirus	O
saimiri	O
tip	O
protein	O
involves	O
two	O
binding	O
interactions	O
.	O
The	O
Tip	B-protein
protein	I-protein
of	O
Herpesvirus	O
saimiri	O
strain	O
484C	O
binds	O
to	O
and	O
activates	O
the	O
Lck	B-protein
tyrosine	I-protein
protein	I-protein
kinase	I-protein
.	O
Two	O
sequences	O
in	O
the	O
Tip	B-protein
protein	I-protein
were	O
previously	O
shown	O
to	O
be	O
involved	O
in	O
binding	O
to	O
Lck	B-protein
.	O
A	O
proline-rich	O
region	O
,	O
residues	O
132-141	O
,	O
binds	O
to	O
the	O
SH3	B-protein
domain	I-protein
of	O
the	O
Lck	B-protein
protein	I-protein
.	O
We	O
show	O
here	O
that	O
the	O
other	O
Lck-binding	B-protein
domain	I-protein
,	O
residues	O
104-113	O
,	O
binds	O
to	O
the	O
carboxyl-terminal	O
half	O
of	O
Lck	B-protein
and	O
that	O
this	O
binding	O
does	O
not	O
require	O
the	O
Lck	B-protein
SH3	I-protein
domain	I-protein
.	O
Mutated	O
Tip	O
containing	O
only	O
one	O
functional	O
Lck-binding	B-protein
domain	I-protein
can	O
bind	O
stably	O
to	O
Lck	B-protein
,	O
although	O
not	O
as	O
strongly	O
as	O
wild-type	O
Tip	O
.	O
Interaction	O
of	O
Tip	O
with	O
Lck	O
through	O
either	O
Lck-binding	B-protein
domain	I-protein
increases	O
the	O
activity	O
of	O
Lck	B-protein
in	O
vivo	O
.	O
Simultaneous	O
binding	O
of	O
both	O
domains	O
is	O
required	O
for	O
maximal	O
activation	O
of	O
Lck	B-protein
.	O
The	O
transient	O
expression	O
of	O
Tip	O
in	O
T	O
cells	O
was	O
found	O
to	O
stimulate	O
both	O
Stat3	B-protein
-dependent	O
and	O
NF-AT	B-protein
-dependent	O
transcription	O
.	O
Mutant	O
forms	O
of	O
Tip	O
lacking	O
one	O
or	O
the	O
other	O
of	O
the	O
two	O
Lck-binding	O
domains	O
retained	O
the	O
ability	O
to	O
stimulate	O
Stat3	B-protein
-dependent	O
transcription	O
.	O
Tip	O
lacking	O
the	O
proline-rich	B-protein
Lck-binding	I-protein
domain	I-protein
exhibited	O
almost	O
wild-type	O
activity	O
in	O
this	O
assay	O
.	O
In	O
contrast	O
,	O
ablation	O
of	O
either	O
Lck-binding	B-protein
domain	I-protein
abolished	O
the	O
ability	O
of	O
Tip	O
to	O
stimulate	O
NF-AT	B-protein
-dependent	O
transcription	O
.	O
Full	O
biological	O
activity	O
of	O
Tip	O
,	O
therefore	O
,	O
appears	O
to	O
require	O
both	O
Lck-binding	O
domains	O
.	O
Accumulation	O
of	O
RXR	B-protein
alpha	I-protein
during	O
activation	O
of	O
cycling	O
human	O
T	O
lymphocytes	O
:	O
modulation	O
of	O
RXRE	O
transactivation	O
function	O
by	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
pathways	O
.	O
We	O
have	O
previously	O
reported	O
that	O
the	O
activation	O
of	O
resting	O
human	O
immature	O
peripheral	O
blood	O
T	O
(	O
PBT	O
)	O
lymphocytes	O
is	O
associated	O
with	O
the	O
loss	O
of	O
retinoid	B-protein
X	I-protein
receptor	I-protein
alpha	I-protein
(	I-protein
RXRalpha	I-protein
)	O
expression	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
have	O
demonstrated	O
that	O
,	O
unlike	O
resting	O
cells	O
,	O
activation	O
of	O
cycling	O
human	O
mature	O
PBT	O
lymphocytes	O
,	O
and	O
T	O
lymphocyte	O
leukemia	O
cell	O
lines	O
is	O
accompanied	O
by	O
the	O
accumulation	O
of	O
RXRalpha	O
mRNA	O
and	O
protein	O
.	O
Interestingly	O
,	O
cyclosporin	O
A	O
further	O
augmented	O
RXRalpha	B-protein
expression	O
,	O
indicating	O
the	O
involvement	O
of	O
calcineurin	B-protein
pathways	O
in	O
the	O
process	O
.	O
9-cis	O
retinoic	O
acid	O
inhibited	O
the	O
accumulation	O
,	O
suggesting	O
that	O
retinoids	O
can	O
regulate	O
the	O
synthesis	O
of	O
their	O
own	O
receptors	O
during	O
T	O
cell	O
activation	O
.	O
Transfection	O
analysis	O
in	O
Jurkat	O
cells	O
,	O
using	O
RXRE-dependent	O
reporter	O
assays	O
,	O
showed	O
that	O
RXRalpha	B-protein
accumulated	O
during	O
T	O
cell	O
activation	O
was	O
transcriptionally	O
inactive	O
.	O
To	O
investigate	O
the	O
mechanism	O
of	O
such	O
inhibition	O
,	O
the	O
role	O
of	O
two	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
pathways	O
,	O
c-Jun	B-protein
N-terminal	I-protein
kinase	I-protein
(	O
JNK	B-protein
)	O
and	O
extracellular	B-protein
signal-regulated	I-protein
kinase	I-protein
(	O
ERK	B-protein
)	O
,	O
in	O
modulating	O
RXRE-dependent	O
transcription	O
,	O
was	O
explored	O
.	O
The	O
expression	O
of	O
constitutively	B-protein
active	I-protein
MAP/ERK	I-protein
kinase	I-protein
kinase	I-protein
1	I-protein
(	O
MEKK1	O
)	O
inhibited	O
RXRE-dependent	O
transcription	O
,	O
whereas	O
dominant	O
negative	O
MEKK1	O
increased	O
the	O
transcription	O
,	O
indicating	O
the	O
involvement	O
of	O
JNK	B-protein
signaling	O
pathways	O
in	O
the	O
process	O
.	O
In	O
contrast	O
,	O
expression	O
of	O
constitutively	O
active	O
MEK1	O
,	O
which	O
activates	O
ERK	O
pathway	O
,	O
enhanced	O
RXRE-dependent	O
activation	O
.	O
When	O
both	O
were	O
activated	O
simultaneously	O
,	O
JNK	O
pathway	O
was	O
dominant	O
over	O
ERK	O
pathway	O
and	O
resulted	O
in	O
inhibition	O
of	O
RXRE-mediated	O
transcription	O
.	O
These	O
data	O
demonstrate	O
a	O
dual	O
regulatory	O
control	O
of	O
RXRalpha	B-protein
expression	O
during	O
the	O
activation	O
of	O
resting	O
and	O
cycling	O
T	O
lymphocytes	O
and	O
indicate	O
a	O
dynamic	O
balance	O
between	O
JNK	B-protein
and	O
ERK	B-protein
pathways	O
in	O
modulating	O
RXRE-mediated	O
transactivation	O
.	O
The	O
proteasome	B-protein
regulates	O
receptor-mediated	O
endocytosis	O
of	O
interleukin-2	B-protein
.	O
Recent	O
studies	O
have	O
increasingly	O
implicated	O
the	O
proteasome	B-protein
in	O
the	O
regulation	O
of	O
cell	B-protein
surface	I-protein
receptors	I-protein
.	O
In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
role	O
of	O
the	O
proteasome	B-protein
for	O
ligand-dependent	O
endocytosis	O
and	O
degradation	O
of	O
the	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	I-protein
-interleukin-2	I-protein
receptor	I-protein
(	O
IL-2R	B-protein
)	I-protein
complex	I-protein
.	O
Proteasome	B-protein
inhibitors	O
impaired	O
internalization	O
of	O
IL-2.IL-2R	O
and	O
prevented	O
the	O
lysosomal	O
degradation	O
of	O
this	O
cytokine	O
.	O
Based	O
on	O
time-course	O
studies	O
,	O
proteasome	B-protein
activity	O
is	O
primarily	O
required	O
after	O
initial	O
endocytosis	O
of	O
the	O
IL-2.IL-2R	O
.	O
Proteasome	B-protein
function	O
was	O
also	O
necessary	O
for	O
the	O
lysosomal	O
degradation	O
of	O
IL-2	B-protein
internalized	O
by	O
IL-2R	B-protein
that	O
were	O
comprised	O
of	O
cytoplasmic	O
tailless	O
beta-	O
or	O
gamma	O
c-subunits	O
,	O
suggesting	O
that	O
the	O
target	O
protein	O
for	O
the	O
proteasome	B-protein
is	O
independent	O
of	O
either	O
the	O
cytoplasmic	O
tail	O
of	O
the	O
IL-2R	O
beta-	O
or	O
gamma	O
c-subunits	O
and	O
their	O
associated	O
signaling	O
components	O
.	O
Therefore	O
,	O
a	O
functional	O
proteasome	B-protein
is	O
required	O
for	O
optimal	O
endocytosis	O
of	O
the	O
IL-2R/ligand	B-protein
complex	I-protein
and	O
is	O
essential	O
for	O
the	O
subsequent	O
lysosomal	O
degradation	O
of	O
IL-2	B-protein
,	O
possibly	O
by	O
regulating	O
trafficking	O
to	O
the	O
lysosome	O
.	O
Functional	O
characterization	O
of	O
the	O
two	O
alternative	O
promoters	O
of	O
human	O
p45	O
NF-E2	O
gene	O
.	O
OBJECTIVE	O
:	O
The	O
transcription	B-protein
factor	I-protein
NF-E2	I-protein
,	O
a	O
heterodimeric	B-protein
protein	I-protein
complex	I-protein
composed	O
of	O
p45	O
and	O
small	O
Maf	B-protein
family	I-protein
proteins	I-protein
,	O
is	O
considered	O
crucial	O
for	O
the	O
proper	O
differentiation	O
of	O
erythrocytes	O
and	O
megakaryocytes	O
in	O
vivo	O
.	O
We	O
report	O
the	O
results	O
of	O
studies	O
aimed	O
at	O
understanding	O
the	O
regulatory	O
mechanisms	O
controlling	O
p45	O
gene	O
expression	O
in	O
erythroid	O
cells	O
.	O
MATERIALS	O
AND	O
METHODS	O
:	O
Human	O
p45	O
mRNAs	O
have	O
two	O
alternative	O
isoforms	O
,	O
aNF-E2	O
and	O
fNF-E2	O
,	O
and	O
these	O
isoforms	O
are	O
transcribed	O
from	O
the	O
alternative	O
promoters	O
.	O
We	O
investigated	O
lineage-specific	O
expression	O
of	O
both	O
isomers	O
in	O
human	O
erythroid	O
and	O
megakaryocytic	O
cells	O
by	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
or	O
Northern	O
blot	O
analysis	O
.	O
For	O
functional	O
characterization	O
of	O
both	O
promoters	O
,	O
plasmids	O
in	O
which	O
reporter	O
genes	O
were	O
placed	O
under	O
the	O
control	O
of	O
a	O
series	O
of	O
truncated	O
or	O
mutated	O
promoter	O
fragments	O
were	O
transfected	O
to	O
human	O
hematopoietic	O
cell	O
lines	O
.	O
RESULTS	O
:	O
When	O
CD34	O
(	O
+	O
)	O
cells	O
isolated	O
from	O
human	O
cord	O
blood	O
were	O
induced	O
to	O
unilineage	O
erythroid	O
or	O
megakaryocytic	O
differentiation	O
in	O
liquid	O
suspension	O
culture	O
,	O
both	O
transcripts	O
,	O
although	O
barely	O
detected	O
at	O
day	O
0	O
,	O
were	O
induced	O
in	O
both	O
erythroid	O
and	O
megakaryocytic	O
cultures	O
.	O
fNF-E2	O
mRNA	O
was	O
found	O
to	O
be	O
more	O
abundant	O
in	O
erythroid	O
cells	O
than	O
megakaryocytic	O
cells	O
at	O
day	O
7	O
of	O
culture	O
.	O
Although	O
both	O
isomers	O
were	O
expressed	O
in	O
human	O
erythroid-megakaryocytic	O
cell	O
lines	O
,	O
megakaryocytic	O
maturation	O
with	O
loss	O
of	O
erythroid	O
phenotype	O
induced	O
by	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
resulted	O
in	O
exclusive	O
downregulation	O
of	O
fNF-E2	O
,	O
suggesting	O
that	O
fNF-E2	O
promoter	O
is	O
more	O
erythroid	O
specific	O
.	O
Functional	O
analysis	O
of	O
fNF-E2	O
promoter	O
showed	O
that	O
the	O
promoter	O
is	O
active	O
only	O
in	O
erythroid-megakaryocytic	O
cells	O
and	O
that	O
the	O
double	B-protein
GATA	I-protein
sit	I-protein
e	I-protein
in	O
the	O
proximal	O
region	O
is	O
necessary	O
for	O
its	O
efficient	O
activity	O
.	O
CONCLUSION	O
:	O
These	O
results	O
suggest	O
that	O
GATA	B-protein
proteins	I-protein
,	O
which	O
govern	O
the	O
differentiation	O
of	O
erythroid	O
lineage	O
cells	O
,	O
are	O
required	O
for	O
full	O
promoter	O
activity	O
of	O
the	O
p45	O
gene	O
.	O
Transcriptional	O
activation	O
of	O
heme	O
oxygenase-1	O
and	O
its	O
functional	O
significance	O
in	O
acetaminophen-induced	O
hepatitis	O
and	O
hepatocellular	O
injury	O
in	O
the	O
rat	O
.	O
BACKGROUND/AIM	O
:	O
Glutathione	O
depletion	O
contributes	O
to	O
acetaminophen	O
hepatotoxicity	O
and	O
is	O
known	O
to	O
induce	O
the	O
oxidative	O
stress	O
reactant	O
heme	O
oxygenase-1	O
.	O
The	O
metabolites	O
of	O
the	O
heme	O
oxygenase	O
pathway	O
,	O
biliverdin	O
,	O
carbon	O
monoxide	O
,	O
and	O
iron	O
may	O
modulate	O
acetaminophen	O
toxicity	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
cell-type	O
specific	O
expression	O
of	O
heme	O
oxygenase-1	O
and	O
its	O
impact	O
on	O
liver	O
injury	O
and	O
microcirculatory	O
disturbances	O
in	O
a	O
model	O
of	O
acetaminophen-induced	O
hepatitis	O
.	O
METHODS	O
:	O
Gene	O
expression	O
of	O
heme	O
oxygenase-1	O
was	O
studied	O
by	O
Northern-	O
and	O
Western	O
analysis	O
as	O
well	O
as	O
immunohistochemistry	O
.	O
The	O
time	O
course	O
of	O
heme	O
oxygenase-1	O
and	O
-2	O
,	O
cytokine-induced	O
neutrophil	O
chemoattractant-1	O
,	O
and	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
was	O
studied	O
by	O
Northern	O
analysis	O
.	O
DNA-binding	O
activity	O
of	O
nuclear	B-protein
factor-kappaB	I-protein
was	O
determined	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O
Sinusoidal	O
perfusion	O
and	O
leukocyte-endothelial	O
interactions	O
were	O
assessed	O
by	O
intravital	O
microscopy	O
.	O
RESULTS	O
:	O
Acetaminophen	O
caused	O
a	O
moderate	O
sinusoidal	O
perfusion	O
failure	O
(	O
-15	O
%	O
)	O
and	O
infiltration	O
of	O
neutrophils	O
along	O
with	O
activation	O
of	O
nuclear	B-protein
factor-kappaB	I-protein
and	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
and	O
cytokine-induced	O
neutrophil	O
chemoattractant-1	O
mRNAs	O
.	O
Induction	O
of	O
heme	O
oxygenase-1	O
mRNA	O
and	O
protein	O
(	O
approximately	O
30-fold	O
)	O
in	O
hepatocytes	O
and	O
non-parenchymal	O
cells	O
paralleled	O
the	O
inflammatory	O
response	O
.	O
Blockade	O
of	O
heme	O
oxygenase	O
activity	O
with	O
tin-protoporphyrin-IX	O
abrogated	O
acetaminophen-induced	O
hepatic	O
neutrophil	O
accumulation	O
and	O
nuclear	B-protein
factor-kappaB	I-protein
activation	O
,	O
but	O
failed	O
to	O
affect	O
sinusoidal	O
perfusion	O
and	O
liver	O
injury	O
.	O
CONCLUSIONS	O
:	O
The	O
inflammatory	O
response	O
associated	O
with	O
acetaminophen	O
hepatotoxicity	O
is	O
modulated	O
by	O
the	O
parallel	O
induction	O
of	O
the	O
heme	O
oxygenase-1	O
gene	O
.	O
However	O
,	O
heme	O
oxygenase-1	O
has	O
no	O
permissive	O
effect	O
on	O
sinusoidal	O
perfusion	O
and	O
does	O
not	O
affect	O
liver	O
injury	O
in	O
this	O
model	O
.	O
These	O
data	O
argue	O
against	O
a	O
central	O
role	O
of	O
nuclear	B-protein
factor-kappaB	I-protein
activation	O
and	O
neutrophil	O
infiltration	O
as	O
perpetuating	O
factors	O
of	O
liver	O
injury	O
in	O
acetaminophen	O
toxicity	O
.	O
Tumor	O
necrosis	O
factor-alpha	O
-induced	O
proliferation	O
requires	O
synthesis	O
of	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
.	O
OBJECTIVE	O
:	O
Tumor	O
necrosis	O
factor-	O
alpha	O
(	O
TNF-alpha	B-protein
)	O
induces	O
a	O
variety	O
of	O
cellular	O
responses	O
,	O
some	O
of	O
them	O
being	O
at	O
least	O
seemingly	O
contradictory	O
.	O
Thus	O
,	O
we	O
set	O
out	O
to	O
find	O
differences	O
in	O
the	O
modes	O
of	O
proliferative	O
and	O
apoptotic	O
responses	O
to	O
TNF-	B-protein
alpha	I-protein
.	O
MATERIALS	O
AND	O
METHODS	O
:	O
We	O
screened	O
a	O
panel	O
of	O
acute	O
myeloid	O
leukemia-derived	O
cell	O
lines	O
for	O
TNF-	O
alpha	O
-responsiveness	O
.	O
In	O
two	O
lines	O
(	O
OCI-AML-1	O
,	O
OCI-AML-11	O
)	O
,	O
TNF-	O
alpha	O
acted	O
as	O
an	O
apoptotic	O
agent	O
;	O
in	O
others	O
(	O
HU-3	O
,	O
M-07e	O
,	O
TF-1	O
)	O
,	O
it	O
had	O
the	O
opposite	O
effect	O
,	O
preventing	O
apoptosis	O
and	O
inducing	O
proliferation	O
.	O
Direct	O
and	O
indirect	O
signaling	O
mechanisms	O
,	O
including	O
NF-kappaB	O
activation	O
and	O
cytokine	O
synthesis	O
,	O
were	O
analyzed	O
.	O
RESULTS	O
:	O
All	O
cell	O
lines	O
tested	O
expressed	O
TNF-	B-protein
alpha	I-protein
receptors	I-protein
I	I-protein
and	I-protein
II	I-protein
and	O
responded	O
to	O
TNF-	O
alpha	O
by	O
upregulation	O
of	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
.	O
In	O
contrast	O
to	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
,	O
TNF-	O
alpha	O
did	O
not	O
activate	O
the	O
MAP	B-protein
kinase	I-protein
and	O
p70S6	O
kinase	O
pathways	O
.	O
Nevertheless	O
,	O
inhibitors	O
of	O
these	O
pathways	O
clearly	O
reduced	O
the	O
TNF-alpha	B-protein
-induced	O
cell	O
growth	O
,	O
indicating	O
that	O
TNF-	O
alpha-proliferative	O
cells	O
produced	O
a	O
growth	B-protein
factor	I-protein
that	O
induced	O
proliferation	O
upon	O
stimulation	O
of	O
the	O
above	O
pathways	O
.	O
Anti-GM-CSF	B-protein
antibodies	I-protein
inhibited	O
the	O
TNF-alpha	B-protein
-induced	O
growth	O
,	O
suggesting	O
the	O
presence	O
of	O
an	O
autocrine	O
loop	O
for	O
cell	O
proliferation	O
mediated	O
by	O
GM-CSF	B-protein
.	O
Supporting	O
this	O
notion	O
,	O
TNF-alpha	B-protein
-induced	O
upregulation	O
of	O
GM-CSF	O
mRNA	O
levels	O
and	O
protein	O
secretion	O
in	O
the	O
TNF-alpha	B-protein
-proliferative	O
,	O
but	O
not	O
in	O
the	O
TNF-alpha-apoptotic	O
cell	O
lines	O
.	O
CONCLUSION	O
:	O
These	O
data	O
identify	O
GM-CSF	O
synthesis	O
as	O
an	O
early	O
and	O
essential	O
step	O
in	O
TNF-	O
alpha-induced	O
proliferation	O
.	O
We	O
show	O
for	O
the	O
first	O
time	O
that	O
TNF-alpha-treated	O
cell	O
lines	O
producing	O
no	O
or	O
only	O
minimal	O
amounts	O
of	O
GM-CSF	B-protein
demonstrate	O
an	O
apoptotic	O
phenotype	O
,	O
while	O
cell	O
lines	O
with	O
high	O
GM-CSF	O
expression	O
rates	O
can	O
escape	O
from	O
growth	O
arrest	O
or	O
even	O
apoptosis	O
.	O
In	O
this	O
context	O
,	O
we	O
discuss	O
arguments	O
pointing	O
at	O
NF-kappaB	B-protein
as	O
regulator	O
of	O
GM-CSF	B-protein
synthesis	O
and	O
thus	O
indirectly	O
as	O
regulator	O
for	O
the	O
escape	O
of	O
TNF-alpha	B-protein
-induced	O
apoptosis	O
Glucocorticoid	B-protein
receptor	I-protein
content	O
of	O
T	O
lymphocytes	O
:	O
evidence	O
for	O
heterogeneity	O
.	O
Glucocorticoid	B-protein
receptors	I-protein
were	O
measured	O
in	O
T	O
lymphocytes	O
that	O
were	O
isolated	O
from	O
peripheral	O
blood	O
by	O
either	O
nylon	O
wool	O
filtration	O
or	O
E-rosette	O
sedimentation	O
.	O
T	O
cells	O
isolated	O
by	O
nylon	O
wool	O
filtration	O
specifically	O
bind	O
6.7	O
+/-	O
0.2	O
fmol	O
of	O
dexamethasone	O
per	O
million	O
cells	O
(	O
equivalent	O
to	O
4000	O
+/-	O
200	O
receptors	O
per	O
cell	O
)	O
,	O
whereas	O
T	O
cells	O
isolated	O
by	O
E-rosette	O
sedimentation	O
bind	O
12.0	O
+/-	O
0.7	O
fmol	O
of	O
dexamethasone	O
per	O
million	O
cells	O
(	O
equivalent	O
to	O
7200	O
+/-	O
400	O
receptors	O
per	O
cell	O
)	O
.	O
This	O
difference	O
in	O
the	O
amount	O
of	O
dexamethasone	O
bound	O
by	O
the	O
two	O
T	O
cell	O
preparations	O
was	O
significant	O
(	O
p	O
less	O
than	O
.001	O
)	O
and	O
was	O
present	O
immediately	O
after	O
cell	O
isolation	O
.	O
The	O
binding	O
affinities	O
of	O
the	O
different	O
T	O
cell	O
preparations	O
for	O
dexamethasone	O
were	O
similar	O
.	O
T	O
cells	O
that	O
are	O
isolated	O
by	O
a	O
combination	O
of	O
nylon	O
wool	O
filtration	O
followed	O
by	O
E-rosette	O
sedimentation	O
bind	O
the	O
same	O
amount	O
of	O
dexamethasone	O
as	O
T	O
cells	O
isolated	O
by	O
nylon	O
wool	O
filtration	O
alone	O
.	O
T	O
cells	O
isolated	O
by	O
a	O
combination	O
of	O
E-rosette	O
sedimentation	O
following	O
by	O
nylon	O
wool	O
filtration	O
bind	O
less	O
dexamethasone	O
than	O
do	O
T	O
cells	O
isolated	O
by	O
E-rosette	O
sedimentation	O
alone	O
.	O
These	O
findings	O
suggest	O
that	O
T	O
cells	O
are	O
heterogeneous	O
with	O
respect	O
to	O
their	O
quantity	O
of	O
glucocorticoid	B-protein
receptors	I-protein
.	O
Isolation	O
of	O
T	O
cells	O
by	O
E-rosette	O
sedimentation	O
enriches	O
for	O
T	O
cells	O
that	O
have	O
a	O
greater	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
,	O
and	O
isolation	O
of	O
T	O
cells	O
by	O
nylon	O
wool	O
filtration	O
enriches	O
for	O
T	O
cells	O
that	O
have	O
a	O
lesser	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
.	O
Glucocorticoid	B-protein
receptors	I-protein
and	O
glucocorticoid	O
sensitivity	O
of	O
human	O
leukemic	O
cells	O
.	O
We	O
have	O
established	O
optimal	O
conditions	O
for	O
the	O
measurement	O
of	O
glucocorticoid	B-protein
receptors	I-protein
(	O
GR	B-protein
)	O
in	O
human	O
white	O
cells	O
using	O
a	O
whole-cell	O
binding	O
assay	O
with	O
[	O
3H	O
]	O
dexamethasone	O
as	O
the	O
ligand	O
,	O
and	O
the	O
subsequent	O
determination	O
of	O
the	O
GR	B-protein
content	O
in	O
normal	O
human	O
lymphocytes	O
and	O
in	O
leukemic	O
cells	O
of	O
patients	O
with	O
various	O
forms	O
of	O
acute	O
and	O
chronic	O
leukemia	O
.	O
A	O
number	O
of	O
leukemia	O
cell	O
lines	O
in	O
continuous	O
culture	O
were	O
also	O
subjected	O
to	O
the	O
GR	B-protein
assay	O
,	O
and	O
the	O
results	O
were	O
correlated	O
with	O
the	O
sensitivity	O
of	O
these	O
cell	O
lines	O
to	O
glucocorticoid	O
steroids	O
in	O
vitro	O
.	O
The	O
GR	B-protein
content	O
of	O
normal	O
human	O
lymphocytes	O
amounted	O
to	O
4	O
,	O
850	O
+/-	O
1	O
,	O
340	O
(	O
mean	O
+/-	O
SD	O
)	O
receptors/cell	O
.	O
The	O
mean	O
equilibrium	O
dissociation	O
constant	O
(	O
KD	O
)	O
of	O
the	O
interaction	O
of	O
[	O
3H	O
]	O
dexamethasone	O
with	O
the	O
GR	B-protein
was	O
1.2	O
x	O
10	O
(	O
-8	O
)	O
M	O
.	O
Steroidal	O
compounds	O
with	O
a	O
known	O
glucocorticoid	O
potency	O
effectively	O
competed	O
for	O
the	O
binding	O
,	O
whereas	O
steroids	O
devoid	O
of	O
glucocorticoid	O
activity	O
(	O
estradiol-17	O
beta	O
and	O
testosterone	O
)	O
were	O
ineffective	O
.	O
The	O
GR	B-protein
content	O
of	O
the	O
blast	O
cells	O
obtained	O
from	O
eight	O
patients	O
suffering	O
from	O
acute	O
leukemia	O
and	O
four	O
patients	O
with	O
a	O
blast	O
crisis	O
of	O
chronic	O
myelocytic	O
leukemia	O
was	O
found	O
to	O
be	O
highly	O
variable	O
(	O
3	O
,	O
230-29	O
,	O
900	O
receptors/cell	O
)	O
,	O
while	O
the	O
lymphocytes	O
of	O
six	O
patients	O
with	O
chronic	O
lymphatic	O
leukemia	O
contained	O
a	O
rather	O
stable	O
GR	O
content	O
(	O
2	O
,	O
930-5	O
,	O
120	O
receptors/cell	O
)	O
,	O
which	O
was	O
comparable	O
with	O
that	O
of	O
normal	O
lymphocytes	O
.	O
GR	B-protein
was	O
identified	O
in	O
all	O
the	O
12	O
malignant	O
continuous	O
white	O
cell	O
lines	O
studied	O
.	O
Large	O
cells	O
contained	O
more	O
GR	B-protein
than	O
the	O
smaller	O
ones	O
.	O
There	O
was	O
no	O
apparent	O
correlation	O
between	O
the	O
GR	B-protein
concentration	O
and	O
the	O
sensitivity	O
of	O
the	O
cells	O
in	O
vitro	O
to	O
glucocorticoids	O
as	O
judged	O
by	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
studies	O
.	O
Distribution	O
of	O
the	O
surface	O
markers	O
in	O
the	O
leukemic	O
cell	O
lines	O
did	O
not	O
relate	O
to	O
the	O
GR	B-protein
concentration	O
.	O
We	O
conclude	O
that	O
the	O
presence	O
of	O
GR	B-protein
is	O
probably	O
a	O
universal	O
feature	O
of	O
the	O
leukemic	O
cells	O
,	O
and	O
,	O
from	O
a	O
clinical	O
standpoint	O
,	O
probably	O
does	O
not	O
alone	O
imply	O
steroid	O
responsiveness	O
.	O
Evidence	O
for	O
a	O
steroid	B-protein
receptor	I-protein
in	O
rheumatoid	O
synovial	O
tissue	O
cells	O
.	O
One	O
mechanism	O
by	O
which	O
glucocorticoids	O
could	O
exert	O
their	O
anti-inflammatory	O
action	O
is	O
via	O
rapidly	O
saturable	O
,	O
stereo-specific	B-protein
cytoplasmic	I-protein
protein	I-protein
receptors	I-protein
.	O
This	O
report	O
is	O
of	O
an	O
investigation	O
into	O
such	O
a	O
possibility	O
in	O
synovial	O
cells	O
.	O
Synovium	O
,	O
obtained	O
from	O
knee	O
joints	O
of	O
rheumatoid	O
patients	O
undergoing	O
surgery	O
,	O
was	O
incubated	O
with	O
clostridiopeptidase	O
A	O
and	O
trypsin-EDTA	O
to	O
obtain	O
cell	O
suspensions	O
.	O
These	O
,	O
together	O
with	O
cells	O
obtained	O
from	O
synovial	O
fluid	O
aspirated	O
from	O
patients	O
with	O
rheumatoid	O
arthritis	O
,	O
were	O
identified	O
by	O
electron	O
microscopy	O
.	O
Duplicate	O
samples	O
of	O
these	O
cell	O
suspensions	O
were	O
incubated	O
with	O
increasing	O
concentrations	O
of	O
H3Dexamethasone	O
(	O
1	O
x	O
10	O
(	O
-10	O
)	O
M-1	O
x	O
10	O
(	O
-9	O
)	O
M	O
)	O
for	O
30	O
minutes	O
at	O
37	O
degrees	O
C	O
.	O
Analysis	O
of	O
the	O
proportion	O
of	O
steroid	O
bound	O
to	O
whole	O
cells	O
showed	O
evidence	O
for	O
specific	O
,	O
rapidly	O
saturable	B-protein
,	I-protein
receptors	I-protein
in	O
the	O
cells	O
obtained	O
from	O
synovial	O
tissue	O
,	O
but	O
this	O
was	O
not	O
found	O
in	O
synovial	O
fluid	O
cells	O
.	O
Electron	O
micrographs	O
showed	O
that	O
cells	O
obtained	O
from	O
synovial	O
tissue	O
consisted	O
of	O
synovial	O
fibroblast	O
-	O
and	O
macrophage-types	O
,	O
lymphocytes	O
,	O
monocytes	O
and	O
macrophages	O
.	O
Polymorphonuclear	O
leucocytes	O
appeared	O
to	O
be	O
absent	O
.	O
However	O
,	O
in	O
synovial	O
fluid	O
cell	O
type	O
polymorphonuclear	O
leucocytes	O
were	O
the	O
predominant	O
cell	O
type	O
.	O
We	O
concluded	O
from	O
this	O
,	O
that	O
one	O
or	O
more	O
of	O
the	O
cell	O
types	O
present	O
in	O
synovial	O
tissue	O
contain	O
a	O
specific	O
steroid	B-protein
receptor	I-protein
,	O
but	O
that	O
this	O
is	O
lacking	O
in	O
synovial	O
fluid	O
polymorphonuclear	O
leucocytes	O
.	O
Clinical	O
implications	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
human	O
leukemia	O
.	O
Glucorticoid	B-protein
receptors	I-protein
were	O
studied	O
in	O
various	O
populations	O
of	O
normal	O
human	O
peripheral	O
blood	O
lymphocytes	O
and	O
leukemic	O
lymphoblasts	O
.	O
Normal	O
lymphocytes	O
contain	O
low	O
levels	O
of	O
glucocorticoid	B-protein
receptor	I-protein
(	O
approximately	O
2	O
,	O
500	O
sites/cell	O
)	O
which	O
are	O
identical	O
in	O
T-	O
and	O
non-T-fractions	O
.	O
Phytohemagglutinin	B-protein
treatment	O
increases	O
levels	O
about	O
3-fold	O
.	O
Leukemic	O
lymphoblasts	O
contain	O
larger	O
numbers	O
of	O
receptor	O
sites	O
.	O
Presence	O
of	O
receptor	O
is	O
correlated	O
with	O
in	O
vitro	O
sensitivitiy	O
to	O
glucocorticoids	O
and	O
in	O
vivo	O
response	O
to	O
therapy	O
.	O
Quantity	O
of	O
receptor	O
is	O
also	O
correlated	O
with	O
complete	O
remission	O
duration	O
independently	O
of	O
leukemic	O
cell	O
type	O
(	O
T	O
or	O
null	O
)	O
,	O
initial	O
WBC	O
,	O
or	O
age	O
of	O
patient	O
.	O
Quantitative	O
determination	O
of	O
glucocorticoid	B-protein
receptor	I-protein
levels	O
in	O
acute	O
lymphoblastic	O
leukemia	O
may	O
be	O
of	O
value	O
both	O
as	O
an	O
independent	O
prognostic	O
variable	O
and	O
in	O
suggesting	O
which	O
patients	O
should	O
receive	O
glucocorticoid	O
therapy	O
.	O
Functional	O
and	O
physical	O
interaction	O
of	O
protein-tyrosine	B-protein
kinases	I-protein
Fyn	B-protein
and	O
Csk	O
in	O
the	O
T-cell	O
signaling	O
system	O
.	O
The	O
Src-like	O
protein-tyrosine	O
kinase	O
Fyn	O
is	O
associated	O
with	O
T-cell	B-protein
antigen	I-protein
receptor	I-protein
.	O
Transient	O
expression	O
of	O
actively	O
mutated	O
Fyn	B-protein
,	I-protein
having	I-protein
Phe-528	I-protein
instead	O
of	O
Tyr-528	O
or	O
Thr-338	O
instead	O
of	O
Ile-338	O
,	O
in	O
Jurkat	O
T-cells	O
stimulated	O
the	O
serum	O
response	O
element	O
(	O
SRE	O
)	O
,	O
12-O-tetradecanoyl-phorbol-13-acetate	O
response	O
element	O
,	O
cyclic	O
AMP	O
response	O
element	O
,	O
and	O
c-fos	O
promoter	O
.	O
The	O
stimulation	O
of	O
SRE	B-protein
was	O
particularly	O
prominent	O
not	O
only	O
with	O
active	O
Fyn	O
but	O
also	O
with	O
normal	O
(	O
wild-type	O
)	O
Fyn	O
.	O
SRE	O
was	O
also	O
stimulated	O
by	O
both	O
normal	O
and	O
active	B-protein
Lck	I-protein
.	O
Furthermore	O
,	O
normal	O
and	O
active	O
Fyn	O
stimulated	O
transcription	O
from	O
the	O
IL-2	O
gene	O
promoter	O
when	O
transfected	O
cells	O
were	O
stimulated	O
by	O
concanavalin	O
A	O
plus	O
12-O-tetradecanoylphorbol-13-acetate	O
.	O
Under	O
the	O
same	O
conditions	O
,	O
Lck	B-protein
did	O
not	O
stimulate	O
IL-2	O
promoter	O
unless	O
it	O
was	O
activated	O
by	O
mutation	O
.	O
Interestingly	O
,	O
a	O
mutant	O
Fyn	O
,	O
which	O
has	O
deletions	O
within	O
the	O
SH2	O
region	O
and	O
so	O
is	O
able	O
to	O
transform	O
chicken	O
embryo	O
fibroblasts	O
,	O
did	O
not	O
stimulate	O
either	O
the	O
c-fos	B-protein
or	O
IL-2	O
promoter	O
,	O
suggesting	O
the	O
importance	O
of	O
this	O
region	O
in	O
T-cell	O
signaling	O
.	O
Csk	O
,	O
which	O
phosphorylates	O
tyrosine	O
residues	O
in	O
the	O
negative	O
regulatory	O
sites	O
of	O
Src	B-protein
family	I-protein
kinases	I-protein
,	O
down-regulated	O
Fyn-	O
and	O
Lck-mediated	O
stimulation	O
of	O
the	O
serum	O
response	O
element	O
and	O
Fyn-mediated	O
enhancement	O
of	O
IL-2	O
promoter	O
activity	O
.	O
These	O
data	O
suggest	O
that	O
Fyn	B-protein
and	I-protein
Lck	I-protein
,	O
whose	O
activities	O
are	O
regulated	O
by	O
Csk	O
,	O
are	O
involved	O
in	O
different	O
phases	O
of	O
T-cell	O
activation	O
.	O
A	O
novel	O
NF-kappa	B-protein
B	I-protein
complex	I-protein
containing	O
p65	B-protein
homodimers	I-protein
:	I-protein
implications	I-protein
for	O
transcriptional	O
control	O
at	O
the	O
level	O
of	O
subunit	B-protein
dimerization	I-protein
.	O
The	O
predominant	O
inducible	O
form	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
transcription	I-protein
factor	I-protein
is	O
a	O
heteromeric	O
complex	O
containing	O
two	O
Rel-related	B-protein
DNA-binding	I-protein
subunits	I-protein
,	O
termed	O
p65	B-protein
and	O
p50	B-protein
.	O
Prior	O
transfection	O
studies	O
have	O
shown	O
that	O
when	O
these	O
p65	B-protein
and	O
p50	B-protein
subunits	I-protein
are	O
expressed	O
independently	O
as	O
stable	B-protein
homodimers	I-protein
,	O
p65	B-protein
stimulates	O
kappa	O
B-directed	O
transcription	O
,	O
whereas	O
p50	O
functions	O
as	O
a	O
kappa	O
B-specific	O
repressor	O
.	O
While	O
authentic	B-protein
p50	I-protein
homodimers	I-protein
(	O
previously	O
termed	O
KBF1	O
)	O
have	O
been	O
detected	O
in	O
nuclear	O
extracts	O
from	O
nontransfected	O
cells	O
,	O
experimental	O
evidence	O
supporting	O
the	O
existence	O
of	O
p65	B-protein
homodimers	I-protein
in	O
vivo	O
was	O
lacking	O
.	O
We	O
now	O
provide	O
direct	O
biochemical	O
evidence	O
for	O
the	O
presence	O
of	O
an	O
endogenous	O
pool	O
of	O
inducible	O
p65	B-protein
homodimers	I-protein
in	O
intact	O
human	O
T	O
cells	O
.	O
As	O
with	O
the	O
prototypical	O
NF-kappa	B-protein
B	I-protein
p50-p65	I-protein
heterodimer	I-protein
,	O
this	O
novel	O
p65	O
homodimeric	O
form	O
of	O
NF-kappa	B-protein
B	I-protein
is	O
functionally	O
sequestered	O
in	O
the	O
cytoplasm	O
but	O
rapidly	O
appears	O
in	O
the	O
nuclear	O
compartment	O
following	O
cellular	O
stimulation	O
.	O
Site-directed	O
mutagenesis	O
studies	O
indicate	O
that	O
the	O
homodimerization	O
function	O
of	O
p65	B-protein
is	O
dependent	O
upon	O
the	O
presence	O
of	O
cysteine	O
216	O
and	O
a	O
conserved	O
recognition	O
motif	O
for	O
protein	B-protein
kinase	I-protein
A	I-protein
(	O
RRPS	O
;	O
amino	O
acids	O
273	O
to	O
276	O
)	O
,	O
both	O
of	O
which	O
reside	O
within	O
a	O
91-amino-acid	O
segment	O
of	O
the	O
Rel	B-protein
homology	I-protein
domain	I-protein
that	O
mediates	O
self-association	O
.	O
In	O
contrast	O
,	O
mutations	O
at	O
these	O
two	O
sites	O
do	O
not	O
affect	O
heterodimerization	O
of	O
p65	B-protein
with	O
p50	B-protein
or	O
its	O
functional	O
interaction	O
with	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O
These	O
later	O
findings	O
indicate	O
that	O
neither	O
homo-	O
nor	O
heterodimer	O
formation	O
is	O
an	O
absolute	O
prerequisite	O
for	O
I	O
kappa	O
B	O
alpha	O
recognition	O
of	O
p65	B-protein
.	O
Taken	O
together	O
with	O
prior	O
in	O
vivo	O
transcription	O
studies	O
,	O
these	O
results	O
suggest	O
that	O
the	O
biological	O
activities	O
of	O
p65	B-protein
and	O
p50	B-protein
homodimers	I-protein
are	O
independently	O
regulated	O
,	O
thereby	O
providing	O
an	O
integrated	O
and	O
flexible	O
control	O
mechanism	O
for	O
the	O
rapid	O
activation	O
and	O
repression	O
of	O
NF-kappa	B-protein
B	I-protein
/	O
Rel	B-protein
-directed	O
gene	O
expression	O
.	O
Carrier	O
determination	O
for	O
X-linked	O
agammaglobulinemia	O
using	O
X	O
inactivation	O
analysis	O
of	O
purified	O
B	O
cells	O
.	O
We	O
report	O
the	O
development	O
of	O
a	O
relatively	O
quick	O
and	O
simple	O
method	O
for	O
the	O
assessment	O
of	O
X	O
inactivation	O
status	O
for	O
carrier	O
determination	O
in	O
families	O
affected	O
by	O
X-linked	O
agammaglobulinemia	O
(	O
XLA	O
)	O
.	O
This	O
method	O
utilises	O
an	O
immunomagnetic	O
separation	O
technique	O
for	O
B	O
cell	O
purification	O
and	O
a	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
based	O
assay	O
for	O
the	O
determination	O
of	O
methylation	O
status	O
at	O
the	O
androgen	B-protein
receptor	I-protein
(	O
AR	O
)	O
gene	O
locus	O
to	O
assess	O
whether	O
X	O
inactivation	O
is	O
random	O
or	O
non-random	O
at	O
this	O
locus	O
.	O
We	O
report	O
the	O
results	O
we	O
have	O
obtained	O
using	O
this	O
assay	O
to	O
investigate	O
females	O
known	O
to	O
be	O
carriers	O
of	O
various	O
X-linked	O
immunodeficiency	O
disorders	O
.	O
In	O
addition	O
,	O
we	O
investigated	O
four	O
females	O
from	O
different	O
families	O
affected	O
by	O
XLA	O
,	O
two	O
of	O
whom	O
were	O
of	O
unknown	O
carrier	O
status	O
,	O
and	O
we	O
discuss	O
the	O
results	O
obtained	O
with	O
this	O
and	O
other	O
X-inactivation	O
assays	O
.	O
A	O
similar	O
assay	O
has	O
recently	O
been	O
described	O
by	O
Allen	O
et	O
(	O
1992	O
)	O
and	O
applied	O
to	O
members	O
of	O
one	O
family	O
affected	O
by	O
XLA	O
.	O
Effects	O
of	O
IL-4	B-protein
and	O
Fc	B-protein
gamma	I-protein
receptor	I-protein
II	I-protein
engagement	O
on	O
Egr-1	O
expression	O
during	O
stimulation	O
of	O
B	O
lymphocytes	O
by	O
membrane	O
immunoglobulin	O
crosslinking	O
.	O
Egr-1	B-protein
is	O
an	O
immediate	O
early	O
gene	O
that	O
is	O
rapidly	O
upregulated	O
in	O
response	O
to	O
mitogenic	O
signals	O
induced	O
by	O
antigen	O
receptor	O
crosslinking	O
on	O
murine	O
B	O
lymphocytes	O
.	O
It	O
has	O
been	O
shown	O
that	O
levels	O
of	O
Egr-1	B-protein
expression	O
are	O
closely	O
correlated	O
with	O
B	O
cell	O
proliferation	O
in	O
several	O
models	O
of	O
B	O
cell	O
activation	O
and	O
tolerance	O
.	O
We	O
compared	O
the	O
expression	O
of	O
Egr-1	B-protein
during	O
B	O
cell	O
stimulation	O
with	O
Fab'2	O
and	O
IgG	B-protein
anti-immunoglobulin	O
(	O
anti-Ig	O
)	O
,	O
since	O
it	O
is	O
known	O
that	O
Fab'2	B-protein
anti-Ig	I-protein
is	O
mitogenic	O
while	O
IgG	B-protein
anti-Ig	I-protein
is	O
not	O
,	O
owing	O
to	O
a	O
dominant	O
inhibitory	O
effect	O
of	O
crosslinking	O
the	O
B	O
cell	O
Fc	O
gamma	O
RII	O
to	O
membrane	O
Ig	O
.	O
While	O
mitogenic	O
doses	O
of	O
Fab'2	O
anti-Ig	O
induce	O
large	O
and	O
rapid	O
increases	O
in	O
Egr-1	O
expression	O
,	O
IgG	B-protein
anti-Ig	I-protein
results	O
in	O
smaller	O
increases	O
in	O
Egr-1	O
mRNA	O
,	O
comparable	O
to	O
that	O
seen	O
with	O
submitogenic	O
concentrations	O
of	O
Fab'2	B-protein
anti-Ig	I-protein
.	O
However	O
